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Essential hypertension is an increase in the systemic arterial blood pressure
without an apparent cause. Hypertension affects about 25% of the world population.
According  to  a  study  conducted  in  urban  areas,  the  prevalence  of  systolic  and
diastolic hypertension in India is 40.9% and 29.3%, respectively (Das,Sanyal, &
Basu, 2005). In India, hypertension is the predominant risk factor for coronary artery
disease (CAD) in all ethnic groups. Therefore, understanding the pathophysiology of
hypertension is important. More than 90% of hypertensive individuals suffer from
essential hypertension. It shows an earlier onset in men, than in women. The factors
linked  to  essential  hypertension  are  age,  obesity,  smoking  and  stress.  A  strong
genetic predisposition is also suggested. Blood pressure is mainly under the control
of blood volume and peripheral resistance, determined predominantly by the
arterioles. It is influenced by hormones as well as by the local factors.  Nitric oxide
(NO), a second messenger  of immense importance in the maintenance of blood
pressure is a vasodilator, which brings down the peripheral resistance.
NO is synonymous with endothelial derived relaxing factor (Katzung, 2004).
It acts via the heme moiety of guanylyl cyclase to produce cyclic guanosine mono-
phosphate (cGMP). This reduces the levels of cytosolic Ca++ and  also
phosphorylates myosin light chain kinase(MLCK). NO decreases the activity of
platelets and neutralizes free radicals. Thus, it plays a major role in preventing
atherosclerosis. It  prevents binding of leucocytes to the endothelium and decreases
inflammation. Hence, it is considered as an important factor in preventing
hypertension. There is a close link between the level of available NO and blood
2pressure. Various studies suggest that, the factors influencing the levels of NO will
have an important role in the pathophysiology and susceptibility to essential
hypertension.
The main source of circulating NO is the endothelium, where it is produced
from the amino acid L-arginine by the action of endothelial nitric oxide synthase
(eNOS). This is a constitutive enzyme with its gene (eNOS/NOS3) on chromosome
7. NOS is a heme protein that exists in its inactive form as a monomer, but dimerizes
before action. NO is  produced by the neurons too, where neuronal nitric oxide
synthase (nNOS/ NOS1), another constitutive enzyme, is responsible for its
production. Inducible nitric oxide synthase (iNOS/NOS2)  on  chromosome  17  is
induced mostly during inflammation. It is responsible for the harmful effects of the
gas. It is expressed in macrophages, smooth muscle cells and hepatocytes and is
responsible for pathological vaso-relaxation. The eNOS is membrane bound, while
the other two are present in soluble form. NO is removed from circulation mostly by
reaction with free radicals, such as superoxide. The balance between the production
and removal of NO is very important with regard to hypertension .
Because eNOS is the major enzyme responsible for nitric oxide production,
variation in its expression and activity can be linked to hypertension. It has been
found that, a G to T polymorphism in the exon 7 region leading to a change from
glutamate at 298 position to aspartate decreases the expression of the enzyme, but
has no effect on the activity (Kato et al., 1999). Another study has suggested that,
such a change causes the enzyme to undergo selective proteolysis (Hingorani, 2003).
3In intron 4 of NOS3, there can be four 27 bp repeats (allele ‘a’) or five (allele
‘b’). Presence of allele ‘a’, rather than the wild-type allele ‘b’, though shows an
increase in the expression of the enzyme, reduces its activity (Kato et al. 1999). The
promoter region T to C polymorphism has also been shown to reduce the expression
of  the  enzyme.  The  association  of  these  polymorphisms  to  hypertension  has  been
controversial. Whereas, the G to T polymorphism has been associated with
hypertension in many ethnic groups (Miyamoto et al., 1998), including the Indian
population (Srivastava K,  Narang R, Sreenivas V, Das S and Das N ,2008), the
association of the other two polymorphisms has been more controversial (Hingorani,
2003; Kato et al., 1999). Few studies have been conducted on Asians, especially
those living in India, regarding these polymorphisms.
             Hence, it is proposed to study the association of serum NO level and eNOS





Affecting 1 billion people worldwide, systemic hypertension remains the
most common, readily identifiable and reversible risk factor for myocardial
infarction, stroke, heart failure, atrial fibrillation, aortic dissection and peripheral
arterial disease. Due to the escalating obesity and population aging in developed and
developing countries, the global burden of hypertension is rising and projected to
affect 1.5 billion persons, one third of the world's population, by the year 2025.
Thus, hypertension one of the world's great public health problems 1 remains as the
leading cause of death, worldwide .
EPIDEMIOLOGY :
The prevalence of hypertension  has been increasing, with 972 million people
suffering from it .
• Incidence rate of hypertension ranges between 3% and 18% , depending on
the age , gender , ethinic groups and body size of the population studied. 25
•  Age and sex adjusted increase in the  prevalence of hypertension from 153.1
per 1000 adults in 1995 to 244.8 per 1000 in 2005, shows  a relative increase
of 60 % .
• Age and sex adjusted increase in the incidence of hypertension from 25.5 per
1000 adults in 1997 to 32.1 per 1000 in 2004   was a relative increase of 25.7
% .
Figure : 1
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5•  Researchers have predicted a relative increase of 24% in the prevalence of
hypertension in developed countries from 2000 to 2025.4
DEFINITION AND CLASSIFICATION OF HYPERTENSION:
            Currently, hypertension is defined as an usual blood pressure of 140/90 mm
Hg or higher levels, for which the benefits of pharmacological treatment have been
definitively established in randomized placebo-controlled trials4 ( Figure : 1)
In  90  to  95  %  of  hypertensive  patients,  a  single  reversible  cause  of  the
elevated blood pressure cannot be identified—hence, the term PRIMARY
HYPERTENSION. In the remaining  5 to 10 % , a more discrete mechanism can be
identified, and the condition is termed SECONDARY OR IDENTIFIABLE
HYPERTENSION.
GENE ENVIRONMENTAL INTERACTION : Hypertension is a multi-
factorial disease, involving both environmental and genetic components.1 (Figure:2)
ENVIRONMENTAL AND BEHAVIORAL DETERMINANTS2 :
In most patients with primary hypertension, readily identifiable behaviors contribute
to the elevated blood pressure.
1. The nicotine in cigarette smoke transiently raises blood pressure by 10 to 20
mm Hg with every single cigarette, thereby elevating the average daytime
blood pressure in habitual smokers.
Figure : 2
GENE ENVIRONMENT INTERACTION IN CAUSATION OF
ESSENTIAL HYPERTENSION
62. With alcohol, the risk of hypertension is lower in moderate drinkers (one or
two drinks per day) than in teetotalers but increased in heavy drinkers (three
or more drinks per day).
3.  Caffeine  consumption  typically  causes  only  a  small  transient  rise  in  blood
pressure which, in some individuals, habituates after the first cup of coffee.
Caffeine consumption does not increase the risk of developing hypertension.5
4. In normotensive individuals, habitual physical inactivity associates with a
markedly increased risk of developing hypertension to certain extent , due to
weight gain.
5. Lifetime dietary habits greatly influence the risk of developing hypertension.
Diets low in fresh fruits, may be associated with an increased risk of
developing hypertension, perhaps because of lower citrate intake.6
6. The two most important dietary determinants of hypertension, however, are
consumption of excessive calories and salt.
7. Across various populations, hypertension prevalence increases linearly with
average body mass index. With the unrelenting obesity epidemic, more than
50% of all cases of hypertension can be attributed to obesity.
8. The risk of developing hypertension is linearly and tightly related to dietary
sodium intake.7 Inter-individual variability in blood pressure, responses to
dietary sodium loading and sodium restriction, indicates an important genetic
underpinning.
7GENETIC DETERMINANTS :
There  are  many  evidences  to  show  that  genetic  factors  contribute  to  blood
pressure regulation  and hypertension.
1.  The normal distribution of blood pressure in the general population indicates
the presence of multiple environmental and genetic factors ; thus, a
polygenic etiology.
2.  Rare monogenic forms of hypertension associated with major defects in salt
handling by the renal system, prove that gene mutations can cause
hypertension, leading to a hypothesis that minor variations in these genes
may contribute to essential hypertension.
3.  From a population perspective, there is a considerable evidence to indicate
the presence of a heritable component  from family aggregation studies.
Hypertension is more common in individuals who have one or two
hypertensive parents and is closely correlated in mono-zygotic than di-
zygotic twins 24,25 .
           It is estimated that, around 30% of variation in blood pressure is due to
genetic factors 23.
In cases of secondary hypertension, it is well proved that genetic mutations
are involved. Fourteen genes have been identified that cause Mendelian forms of
hypertension.8Some of the examples are
8• Liddle's syndrome is a disorder associated with hypertension, low plasma
renin and    aldosterone levels  with hypokalemia, responding to amiloride,
an inhibitor of the distal renal epithelial sodium channel.
• Glucocorticoid-remediable aldosteronism is a disorder mimicking Conn's
syndrome, with a chimeric gene formed from portions of the 11?-
hydroxylase gene and the aldosterone synthase gene. This defect resulting  in
hyper-aldosteronism ,  responding to dexamethasone, presents with a high
incidence of stroke.
• Congenital adrenal hyperplasia due to 11?-hydroxylase deficiency is a
disorder that has been associated with 10 different mutations of the
CYP11B1 gene.
•  Syndrome of apparent mineralocorticoid excess, due to mutations in the
gene encoding the renal enzyme 11?-hydroxysteroid dehydrogenase, allows
normal  circulating  concentrations  of  cortisol   to  activate  the
mineralocorticoid receptors.
• Congenital adrenal hyperplasia with 17?-hydroxylase deficiency, is a
disorder with hypo-reninemia, hypoaldosteronism due to hypokalemia (due
to urinary potassium wasting) and absence of secondary sexual
characteristics.
• Gordon's syndrome (pseudo-hypoaldosteronism) is associated with familial
hypertension and  hyperkalaemia, possibly related to the long arm of
chromosome 17.
9• Sporadic case reports show familial inheritance of phaeochromocytoma
(multiple endocrine neoplasia, MEN-II syndrome), Cushing's syndrome,
Conn's syndrome and renal artery stenosis due to fibromuscular dysplasia.
Various studies are being conducted to explore the genes involved in
essential hypertension :
• The angiotensinogen gene may be related to hypertension. Whereas,
angiotensin converting  enzyme gene may be related to left ventricular
hypertrophy or hypertensive nephropathy.
• ?-adducin gene mutation may be associated with salt sensitive hypertension.
This presents  with sodium retention due to a faster transport across the Na,
K-ATPase pump.
? eNOS gene polymorphism may be associated with hypertension , by
influencing serum NO level.
HEMODYNAMIC SUBTYPES OF ESSENTIAL HYPERTENSION :
           Hypertension can be divided into three distinct  hemodynamic subtypes, that
vary sharply by age.2
DIASTOLIC HYPERTENSION IN MIDDLE AGE :
        When hypertension is diagnosed in middle age (typically from 30 to 50 years of
age), the most common blood pressure pattern is, elevated diastolic pressure with
systolic pressure being normal (isolated diastolic hypertension) or elevated
(combined systolic-diastolic hypertension). This is classic “ESSENTIAL
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HYPERTENSION.” Isolated diastolic hypertension is more common in men and is
often associated with middle-age weight gain.9 Without treatment, isolated diastolic
hypertension often progresses to combined systolic-diastolic hypertension. The
fundamental hemodynamic fault is an elevated systemic vascular resistance coupled
with an inappropriately normal cardiac output. Vasoconstriction at the level of the
resistance arterioles, results from an increased neuro-hormonal drive and an
autoregulatory reaction of vascular smooth muscle to an expanded plasma volume,
the latter is due to impairment in the renal ability to excrete sodium.
ISOLATED SYSTOLIC HYPERTENSION IN OLDER ADULTS :
After  60 years, isolated systolic hypertension (systolic blood pressure above
140 mm Hg and diastolic blood pressure below 90 mm Hg) is the most common
form10. Isolated systolic hypertension may represent an exaggeration of this age-
dependent stiffening process compared with young or middle-aged adults with
optimal blood pressure. Those with blood pressure in the high-normal range
(borderline or pre-hypertension) are much more likely to develop isolated systolic
hypertension after  60 years9.
ISOLATED SYSTOLIC HYPERTENSION IN YOUNG ADULTS :
At the other end of the age spectrum is isolated systolic hypertension in
young  adults  who  are  typically  17  to  25  years  of  age.  The  key  hemodynamic
abnormalities are, increased cardiac output and a stiff aorta, both presumably
reflecting an overactive sympathetic nervous system11.
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MECHANISMS OF PRIMARY (ESSENTIAL) HYPERTENSION :
A number of physiological mechanisms are involved in the maintenance of
normal blood pressure and, their derangement may play a role in the development of
essential hypertension.
Many inter-related factors contribute to the raised blood pressure in
hypertensive patients and their relative roles may differ between individuals. The
factors that have been intensively studied are salt intake, obesity / insulin resistance,
the  renin-angiotensin  system  and  the  sympathetic  nervous  system.  In  the  past  few
years, other factors have been evaluated including genetics, endothelial dysfunction
(as manifested by changes in endothelin and nitric oxide), low birth weight &
intrauterine nutrition and neurovascular anomalies.
1. NEURAL MECHANISMS :
In young adults, primary hypertension consistently is associated with
increased heart rate and cardiac output, increased plasma and urinary norepinephrine
levels, regional norepinephrine spillover, peripheral postganglionic sympathetic
nerve firing (by microelectrode recordings) and alpha-adrenergic receptor–mediated
vasoconstrictor tone in the peripheral circulation12,13. Central sympathetic outflow
can be driven by deactivation of inhibitory neural inputs (e.g., baroreceptors),
activation of excitatory neural inputs (e.g., carotid body chemoreceptors, renal
afferents) or by circulating angiotensin II , which activates pools of excitatory brain
stem neurons, that are devoid of a blood-brain barrier.
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BARORECEPTORS AND HYPERTENSION :
In hypertension, the baroreceptors are reset to defend a higher level of blood
pressure. Baro-reflex control of sinus node function is impaired even in mild
hypertension, but baroreflex control of systemic vascular resistance and blood
pressure is well preserved. Partial baroreceptor dysfunction is common in elderly
hypertensives and typically presents with a triad of orthostatic hypotension, supine
hypertension and symptomatic postprandial hypotension, the latter initiated by
splanchnic pooling after carbohydrate-rich meals14.
OBESITY-RELATED HYPERTENSION:
Neural mechanisms of obesity-related hypertension deserve special mention.
With weight gain, reflex sympathetic activation is thought to be an important
compensation to burn fat but, at the expense of sympathetic over-activity in target
tissues (i.e., vascular smooth muscle and kidney) that produce hypertension15. Near-
maximal rates of sympathetic firing are seen in hypertensive patients with the
metabolic syndrome, with or without “new-onset type 2 diabetes”. Although the
sympathetic activation associates with insulin resistance, the precise stimulus to
sympathetic outflow is unknown ( leptin, other adipokines, and angiotensin-II being
potential candidates).
SLEEP APNEA AS A CAUSE OF NEUROGENIC HYPERTENSION :
The strongest evidence for sustained neurogenic hypertension in humans is,
in patients with obstructive sleep apnea. With repeated arterial de-saturation during
apneas, activation of carotid body chemoreceptors not only causes dramatic pressor
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episodes  throughout  the  night  but,  also  resets  the  chemoreceptor  reflex.  Daytime
normoxia is misinterpreted as hypoxia, producing sustained reflex sympathetic
activation and hypertension, even during waking hours16. Obstructive sleep apnea
not only predisposes to hypertension, but also accelerates the risk of several
hypertensive complications (e.g., stroke, atrial fibrillation and cardiovascular death)
beyond that explained by blood pressure elevation alone17.
2. RENAL MECHANISMS :
The kidney is the culprit as well as the victim in hypertension, producing a
vicious cycle of progressive renal dysfunction and hypertension. In many forms of
experimental and human hypertension, the fundamental abnormality is an acquired
or inherited defect in the renal ability to excrete the excessive sodium load imposed
by a  high sodium chloride diet. Renal sodium retention expands the plasma volume,
increasing cardiac output and triggering auto-regulatory responses that increase
systemic vascular resistance. Salt retention  augments the smooth muscle contraction
produced by all known endogenous vasoconstrictor substances.
LOW BIRTH WEIGHT :
Low birth weight with reduced nephrogenesis,  increases the risk of
developing adult salt-sensitive hypertension. Adult hypertensives having fewer
glomeruli per kidney but very few obsolescent glomeruli, suggest that nephron drop-




Animal and human studies have implicated an important genetic contribution
to salt-sensitive hypertension. Rats with in-bred defects in the kidneys' ability to
excrete sodium, remain relatively normotensive on a sodium-restricted diet but
become severely hypertensive when fed with a high-sodium diet, a model of salt-
sensitive hypertension that can be cured by renal transplantation.
3. HORMONAL MECHANISMS: RENIN-ANGIOTENSIN-ALDOSTERONE
SYSTEM  ( Figure : 3 ) :
Activation of the renin-angiotensin-aldosterone system (RAAS) is one of the
most important mechanisms contributing to endothelial cell dysfunction, vascular re-
modeling, and hypertension . Renin, a protease produced solely by the renal
juxtaglomerular cells, cleaves angiotensinogen (renin substrate produced by the
liver) to angiotensin-I, which is converted by angiotensin-converting enzyme (ACE)
to angiotensin-II . ACE is most abundant in the lungs but is also present in the heart
and systemic vasculature (tissue ACE).  Chymase, a serine protease in the heart and
systemic arteries, provides an alternative pathway for conversion of angiotensin-I to
angiotensin-II. The interaction of angiotensin-II with G protein–coupled
angiotensin-1 receptors activates numerous cellular processes that contribute to
hypertension and accelerate hypertensive end-organ damage . These include
vasoconstriction, generation of reactive oxygen species, vascular inflammation,
vascular and cardiac remodeling and production of aldosterone, the principal
mineralocorticoid. There is increasing evidence that aldosterone, angiotensin-II, and
Figure : 3
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM
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even renin and pro-renin activate multiple signaling pathways, that can damage
vascular health and cause hypertension.
ALDOSTERONE AND EPITHELIAL SODIUM CHANNEL REGULATION :
RAAS activation is a major homeostatic mechanism to counter hypovolemic
hypotension  (as  with  hemorrhage  or  salt  and  water  deprivation).  Interaction  of
aldosterone with cytosolic mineralocorticoid receptors in the renal collecting duct
cells,   recruits  sodium  channels  from  the  cytosol  to  the  surface  of  the  renal
epithelium. The epithelial sodium channels (eNaCs) so recruited increase sodium re-
absorption, thereby re-expanding plasma volume.
             So, in the setting of high dietary sodium and elevated blood pressure, the
RAAS should be completely suppressed, and any degree of RAAS activity is
inappropriate. In normotensive individuals, the risk of developing hypertension
increases with increasing levels of serum aldosterone,  that are well within the
normal range.20 In African Caribbean hypertensives, serum aldosterone levels are
higher than in white hypertensives, despite lower plasma renin levels,21 implicating
abnormal aldosterone production by renin-independent mechanisms,  a form of
primary aldosteronism. By stimulating mineralocorticoid receptors in the heart and
kidney, circulating aldosterone may contribute to the development of cardiac and
renal fibrosis in hypertension22. By stimulating mineralocorticoid receptors in the
brain stem, aldosterone also may contribute to sympathetic overactivity.
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RECEPTOR-MEDIATED ACTIONS OF ANGIOTENSIN II :
Two main types of angiotensin receptors are known. Angiotensin-1 receptors
are widely expressed in the vasculature, kidney, adrenals, heart, liver and brain.
Angiotensin-1 receptor activation explains most of the hypertensive actions of
angiotensin-II. Furthermore, enhanced angiotensin-1 receptor mediated signaling,
provides a central mechanistic explanation for the frequent coexistence of elevated
blood pressure with insulin resistance and atherosclerosis.  Angiotensin 2 receptors
are widely distributed in the fetus but, in adults, are found only in the adrenal
medulla, uterus, ovary, vascular endothelium and distinct brain regions.
4. VASCULAR MECHANISMS:
Alterations  in the structure and function of small and large arteries play a
pivotal role in the pathogenesis and progression of hypertension. The endothelial
lining of blood vessels is critical to vascular health and constitutes a major defense
against hypertension.
Various studies have been carried out which had revealed the importance of
endothelium in regulating vascular function :
? In 1977, Moncada et al published the first report indicating that, the
endothelium  plays  a  central  role  in  the  control  of  vascular  tone  via  the
production of vasoactive substances 26.
? In 1980, Furchgott and Zawadzki 27 demonstrated in an experimental
preparation of the rabbit aorta, the obligatory role played by endothelial cells
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in vascular relaxation in response to effectors like acetylcholine and
postulated the existence of a vascular relaxing factor, derived from the
endothelium.
?  In 1987, two research groups, lead by Ignarro et al 28 and by Palmer et al 29
demonstrated that the relaxing factor derived from the endothelium was NO
an odorless gas until then, considered as a mere pollutant.
? Endothelial dysfunction was first characterized in humans in 1986 by
Ludmer et al30 , who demonstrated that atherosclerotic coronary arteries
contracted in response to intracoronary infusion of acetylcholine, while
normal coronaries showed dilatation.
? In 1992, endothelial dysfunction was documented by Celermajer et al 31 in
children and otherwise healthy young adults with risk factors for
atherosclerosis.
? Recent clinical studies have demonstrated that, some drugs well known to
reduce the incidence of cardiovascular events, improve endothelial function
43-46.
THE  ENDOTHELIUM  IN CARDIOVASCULAR HOMEOSTASIS :
Vascular endothelium may be considered a dynamic, heterogeneous organ,
having secretory, synthesizing, metabolic and immunological functions, vital to
human beings 47.  The  endothelium  regulates  the  flow  of  nutrient  substances  of
various biologically active molecules and of blood cells through the entire human
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body. It is selectively permeable, possessing various cell membrane receptors for
molecules that include proteins (growth factors, coagulation, and anticoagulation
proteins), lipid-transporting particles (LDL), metabolites (nitric oxide, serotonin)
and hormones (endothelin-1). Under physiological conditions, the endothelium
keeps a reduced vasomotor tone, prevents leukocyte /platelet adhesion and inhibits
the proliferation of vascular smooth muscle cells .
The endothelium possesses important anticoagulant, anti-platelet and
fibrinolytic actions. Endothelial cells are the largest sites of reactions involving
thrombin 48.  Some of the stimuli  that  activate platelets (adenosine diphosphate and
thrombin),  stimulate the release of prostacyclin by the endothelium, inhibiting
platelet aggregation 26,49. In response to stimuli like nor-adrenaline, vasopressin,
thrombin and vascular stasis, endothelial cells secrete tissue plasminogen
activator 50,  a  potent  thrombolytic  agent  with  wide  clinical  application,  thus
providing a defense against uncontrolled coagulation. Other hemostatic factors
secreted by the endothelium, include plasminogen activating factor (PAI-1)
inhibitor, Von Willebrand factor and thrombomodulin. When stimulated by certain
physical or chemical factors, the endothelial cell undergoes phenotypical
modifications that determine its transformation into a thrombogenic surface. The
dynamic equilibrium existing between these two states often permits the endothelial
cell to return to its basal state, once the thrombogenic stimulus has ceased.
ENDOTHELIAL VASOMOTOR FUNCTION : (Figure : 4)
 The endothelium plays a central role in the regulation of vascular tone and
blood flow, by the secretion and capture of paracrine vasoactive substances, which
Figure 4 :
ROLE OF ENDOTHELIUM IN REGULATING BLOOD PRESSURE
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includes vasodilator substances (NO, prostacyclin & endothelium-derived
hyperpolarizing factor ) and vasoconstrictor substances ( endothelin-1 , thrombaxane
A2 & platelet-activating factor).
VASODILATORS :
NO is the main mediator of vasomotor tone regulation in physiological
situations, small amounts being continuously secreted by the endothelial cells 29,51 to
maintain a reduced arterial tone in the systemic and pulmonary circulation 52. The
vasodilator  activity  of  NO is  due  to  its  interaction  with  the  iron  atom of  the  heme
prosthetic group of guanylyl cyclase, causing its activation and increasing the
intracellular levels of cyclic guanosine monophosphate (cGMP) 53. In smooth muscle
cells, this decreases intracellular calcium concentration, causing vascular
relaxation54.
Prostacyclin is synthesized from arachidonic acid by cyclo-oxygenase 26,
being rapidly produced and released from endothelial cells55, in response to humoral
and hemodynamic factors. It interacts synergistically with nitric oxide, causing
vasodilation & inhibition of platelet adhesion and aggregation 56. The stimulation of
adenylyl cyclase and increased intracellular concentration of cAMP in smooth
muscle cells and platelets mediate its actions. Prostacyclin does not appear to be
continuously produced by endothelial cells 57,  but  to  be  synthesized  in  response  to
specific stimuli like bradykinin, adenosine diphosphate, hypoxia, and  shear stress.
Endothelium-derived hyperpolarizing factor, another vasodilator
substance produced by the endothelium, promotes vascular smooth muscle cell
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relaxation by increasing cell membrane conductance of potassium 58. This factor is
also secreted in response to acetylcholine and blocked by Ouabain, an inhibitor of
Na/K ATPase. The endothelium-derived hyperpolarizing factor has not yet been
isolated and its physiological role remains uncertain.
VASOCONSTRICTORS :
. Endothelins26  ( Figure 5 ) constitute a family of polypeptides produced by
various cell types. Of the three isoforms known, endothelial cells appear to produce
only endothelin-1. This is a 21 amino-acid peptide formed from its inactive
precursor pre-endothelin-1, by endothelin converting enzyme. It plays its role as an
arterial blood flow regulator in both normal and pathologic conditions 59.
Endothelin-1 formation and release are stimulated by angiotensin II, anti-diuretic
hormone, thrombin, cytokines, reactive oxygen species, hypoxia and shearing forces
acting on the vascular endothelium. Endothelin -1 release is inhibited by
prostacyclin and atrial natriuretic peptide as well as by NO. Binding to specific
receptors in vascular smooth muscle cells it increases intracellular concentration of
calcium, leading to vasoconstriction60 . Intra-myocardial vessels are more sensitive
to endothelin, suggesting that this peptide plays a major role in control of blood
flow. It is interesting that, in functionally intact endothelia, endothelin stimulates the
production of NO and of prostacyclin, which, therefore, modulates vasoconstrictor
action and reduces the synthesis of endothelin itself. Two types of vascular receptors
for endothelin have been identified. Receptor endothelin B is observed in endothelial
cells, being responsible for the stimulation of NO and prostacyclin formation. Both
the endothelin receptors, observed in smooth muscle cells, mediate contraction and
Figure : 5
ENDOTHELIN RECEPTORS AND ITS INTERACTION WITH NITRIC
OXIDE
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proliferation of these cells. A large number of endothelin receptor antagonists
developed in recent years, are being tested experimentally and clinically.
Thromboxane A2 and prostaglandin H2 are  constrictor  factors  also
secreted by the endothelium. They activate the thromboxane receptor in smooth
muscle cells and platelets, in opposition to the effects of NO and prostacyclin.
However, the role of these substances in coronary circulation has not been clearly
established. Platelet activation factor is another vasoconstrictor synthesized and
released by endothelial cells in response to humoral and hemodynamic stimuli,
which probably participates in the regulation of vasomotor tone.
Finally, the endothelium  expresses the ACE, which metabolizes bradykinin.
In addition,  angiotensin II  directly stimulates the production of endothelin.
PATHOPHYSIOLOGY OF ENDOTHELIAL DYSFUNCTION :
Endothelial dysfunction is  characterized   by  the  reduction  of  the
endothelium-derived vasodilators, by local increases in antagonists to these
substances or by an association of these two factors . Endothelial dysfunction
appears to play a pathogenic role in the initial development of atherosclerosis32-34
and of unstable coronary syndromes35,  and  their  diverse  risk  factors   viz
hypercholesterolemia36, smoking37, hypertension 38, diabetes mellitus 39, family
history of premature coronary disease 40, hyperhomocysteinemia 41 and aging 42.
NO and endothelin are the two main factors involved in endothelial
dysfunction. High plasma concentrations of endothelin-1 have been reported in
myocardial infarction, cardiogenic shock, unstable angina pectoris, coronary artery
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disease in general, cardiac failure and essential hypertension 73,74. Endothelin-1
action, unopposed by NO, tends to promote vasoconstriction and proliferation of
vascular smooth muscle cells in states of endothelial dysfunction75.
Reduction in the synthesis or local availability of NO have been frequently
considered the most important cause of endothelial dysfunction in various clinical
conditions. NO release from the endothelium, is decreased in patients with
established coronary atherosclerosis and hypertension30,61,62. A reduction in vascular
availability of NO determines damage to the endothelium-dependent vasodilation,
an increased tendency for platelet aggregation and adhesion of monocytes to the
endothelium, thus influencing the proliferation of vascular smooth muscle cells,
contributing to the onset and progression of hypertension.
NITRIC OXIDE AS THE MEDIATOR OF MANY THERAPEUTIC DRUGS :
The NO pathway contributes to the blood pressure lowering effects of the
commonly used therapeutic agents. Emerging basic research on this pathway is
elucidating potential new antihypertensive drug targets.
Some of the examples are:
1. HMG-CoA reductase inhibitors (statin drugs) have been shown to increase
eNOS expression in the vessel wall280-281 , which may account in part for the blood
pressure lowering effects to a moderate extent .
2.Estrogen replacement therapy increases expression of both eNOS and
nNOS in rats282 . These effects could underlie some of the cardioprotective effects of
estrogen and explain why postmenopausal estrogens do not cause hypertension.
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3.  Some  of  the  antihypertensive  action  of  ACE  inhibitors  is  due  to  the
decreased breakdown of bradykinin,  resulting in receptor-mediated activation of
eNOS and thus improved endothelial-mediated vasodilation275.
4. In addition, excessive NO mediated vasodilation accounts for the marked
and sometimes fatal hypotensive response to nitrates in patients receiving sildenafil,
a phosphodiesterase inhibitor283.
 5. NO donors, such as nitroglycerin, cause vasodilation by increasing cGMP
in the vessel wall and this increase is augmented when its breakdown is prevented
by phosphodiesterase inhibition.275, 283
NITRIC OXIDE :
First studied in 1772 by Joseph Priestly, who called it "nitrous air," nitric
oxide was first discovered as a colorless, toxic gas. It was through various researches
it was found to be a signaling molecule and involved in various physiological
functions .
? In the 1970s, Ferid Murad and his colleagues demonstrated that soluble
guanylate cyclase (sGC) was stimulated by nitrogen-containing compounds,
causing an increase in cGMP, which in turn brought about vascular
relaxation 213,214.
? Murad first showed that the activation of sGC by nitrovasodilators could
occur via the formation of NO. He was fascinated by the idea that a gas and
free radical could regulate smooth muscle function and proposed that
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hormones and other endogenous factors may also act through NO, which
functions  as a messenger, was proposed for the first  time 215,216.
? In 1980, Furchgott and his colleagues published an article 217underlining the
obligatory role of endothelial cells in the acetylcholine-induced relaxation of
arterial smooth muscle and recognized that vasodilation by bradykinin,
histamine and adenosine diphosphate  was due to the same relaxing
substance, which they named endothelial derived relaxing factor (EDRF).
? It was Ignarro 211 who went on to conclude that EDRF from the artery and
vein is either NO or a chemically related radical species in 1987 after Murad
suggested 218that,  EDRF was an "endogenous nitrovasodilator".
Subsequently, Salvador Moncada's group revealed that NO release accounts
for the biological activity of EDRF212.
? By the early 1980's, scientists had conclusively proven that, NO occurred
naturally within the human body. By 1987, its role in regulation blood
pressure and relieving heart conditions was well-established. Two years later,
research revealed that NO is used by macrophages to kill tumor cells and
bacteria.
? In 1992, NO was voted "Molecule of the Year" by Science magazine.
?  On October 12, 1998, the Nobel Assembly awarded the Nobel prize in
Medicine or Physiology to scientists Robert Furchgott, Louis Ignarro, and
Ferid Murad for their discoveries concerning NO as a signaling molecule in
Figure :6
ACTIONS OF NITRIC OXIDE ON VASULATURE
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the cardiovascular system, opening up a new way of treatment for millions of
patients.
? In 1999, it was reported that, the most highly cited U.K. biomedical scientist
of that decade was S. Moncada, because of the work of his group on NO .
? Now, in 2010, more than 70,000 scientific papers have been published on
NO and its seemingly endless role in health and physiology.
NITRIC OXIDE PATHWAY :
NO is produced by the enzyme nitric oxide synthase (NOS) 275  which
catalyzes a five electron oxidation of a guanidino nitrogen of L-arginine (L-Arg).
Oxidation of L-Arg to L-citrulline occurs via two successive mono-oxygenation
reactions producing NGhydroxy L-arginine as an intermediate. Two moles of O2 and
1.5. moles of NADPH are consumed per mole of  NO formed 213 . NO has various
physiological actions as shown in Figure :6
 NO BASED CELL SIGNALING :
I. cGMP dependent signaling ( Figure : 7 )
NO diffuses into the nearby target cells to interact with specific molecular
targets. NO regulates protein activity by reversibly binding to the available acceptor
functionalities, including heme iron and thiols 297The interaction between NO and
the enzyme guanylyl cyclase, which mediates target cell responses such as vascular
smooth muscle relaxation and platelet inhibition, has been well characterized 298,299.
After entering the target cell, NO binds to the heme moiety of guanylyl cyclase and
Figure : 7
cGMP DEPENDENT NITRIC OXIDE PATHWAY :
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activates the enzyme by inducing a conformational change that displaces iron out of
the plane of the porphoryrin ring 300 Guanylyl cyclase then catalyzes the production
of  cyclic  GMP  from  GTP  to  elevate  cyclic  GMP,  which  triggers  a  cascade  of
intracellular events that brings about a reduction in calcium-dependent vascular
smooth muscle tone, by inactivating myosin light chain kinase (MLCK) 301,302.
MLCK normally phosphorylates the regulatory set of myosin light chain. This event
activates cross-bridge cycling and initiates contraction 303. cGMP modulates MLCK
activity by activating a cGMP-dependent protein kinase that phosphorylates MLCK .
Phosphorylation of MLCK diminishes its affinity for calmodulin and, as a
consequence, decreases the phosphorylation of myosin light chain, which in turn
stabilizes the inactive form of myosin. In this manner, cGMP may induce
vasorelaxation by indirectly decreasing myosin light chain-dependent myosin
activation.
GUANYLYL CYCLASE :
Soluble GC(sGC) is a heme-containing, heterodimeric NO receptor. sGC
consists of two subunits, ? and ?, which make up the active enzyme.  sGC isoforms,
products of four genes, have been identified so far as ?1,  ?2,  ?1 and  ?2.  Only  ?1??1
and ?2??1 heterodimers are activated by NO 220. The ?1??1 sGC is the most abundant
isoform 221. Vascular smooth muscle and endothelial cells express predominantly ?1
and ?1 subunits 222. The functional importance of ?1??1 sGC was demonstrated by the
significantly decreased relaxing effects of major vasodilators such as acetylcholine,
NO, YC-1 and BAY 41-2272 in the ?1 sGC knockout mice223 . Through the
production  of  cGMP,  sGC can  exert  many physiological  effects  such  as  mediating
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vascular smooth muscle tone and motility, phototransduction, and maintaining fluid
and electrolyte homeostasis 224-226. The sGC activity increases more than 200 fold in
response  to  NO227,228.  This  signal  is  quickly  removed  by  the  action  of
phosphodiesterase 5A enzyme.
PHOSPHODIESTERASE INHIBITORS :
Phosphodiesterases (PDEs) are intracellular enzymes that specifically
catalyze the hydrolysis of the second messengers cAMP and cGMP to the inactive
metabolites AMP and GMP. By counterbalancing cGMP production by guanylyl
cyclases, PDE5 is able to decrease cGMP levels very effectively. Thus PDE5
inhibition increases intracellular cGMP levels and initiates a cGMP-driven cascade
of reactions 224. Inhibitors of PDE5A such as sildenafil are widely used to treat
erectile dysfunction, but growing evidence supports important role of the enzyme in
both the vasculature and heart. These agents may also be beneficial in other
disorders, such as pulmonary hypertension, Raynaud's syndrome, etc.
SPLICE FORMS AS NOVEL GENETIC REGULATORS OF sGC :
Recently, the vital importance of sGC for mammalian physiology was
directly confirmed by generation of sGC knockout mice 223,229,230. The absence of
sGC protein resulted in a significant increase in blood pressure, complete loss of
NO-dependant aortic relaxation and platelet aggregation in knockout animals, which
died prematurely at the age of 4 weeks due to severe gastrointestinal disorders 229.
sGC function is affected not only by NO, but also by regulation of the expression of
sGC subunits at transcriptional and post-transcriptional levels. The steady state
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mRNA  levels  of  ?1 and  ?1 subunits decrease with hypertension, ageing and vary
during embryonic development 231. The expression of sGC subunits is regulated by
estrogen 232, cAMP-elevating compounds 233,234, cytokines 235 and NO donors 236.
Gene therapy with ?1? ?1 subunits may provide future therapeutic utility in
hypertension.
ALLOSTERIC EFFECTORS OF sGC :
          There are many allosteric regulators of sGC which provide NO independent
activation. Current therapies that involve the use of organic nitrates and other NO
donors have limitations, including non-specific interactions of NO with various
biomolecules, lack of response and the development of tolerance following
prolonged administration. Compounds that activate sGC in an NO-independent
manner might therefore provide considerable therapeutic advantages 238. NO-
independent but heme-dependent stimulators of sGC areYC-1, BAY 41-2272, BAY
41-8543, A-350619 and CFM-1571. NO as well as heme-independent sGC
activators are BAY 58-2667 and HMR-1766.
II.  cGMP INDEPENDENT SIGNALING :
A. Nitrite and nitrate  (Figure : 8 ):
 Nitrite is an oxidative breakdown product of NO that has been shown to
serve as an acute marker of NO formation 243. Nitrite has recently moved to the
forefront of NO biology 244 as, it represents a major storage form of NO in blood and
tissues 245 Much of the recent focus on nitrite physiology is due to its ability to be
Figure : 8
NITRIC OXIDE END PRODUCTS – NITRATE AND NITRITE
29
reduced to NO 239-242, during ischemic or hypoxic events 245. They get converted to
NO and exerts its physiological events . Evidences for this fact include :
? enriching dietary intake of nitrite and nitrate translates into significantly less
injury from heart attack 239.
?  nitrite therapy given intravenously prior to reperfusion protects against
myocardial  injury 251,252 and cerebral vasospasm 253.
? inhalation of nitrite selectively dilates the pulmonary circulation under
hypoxic conditions in vivo in sheep 254.
?  topical application of nitrite improves skin infections and ulcerations 255.
? oral nitrite has also been shown to reverse L-Nitro Arginine Methyl Ester (L-
NAME) induced hypertension and serve as an alternate source of NO in vivo
256.
? plasma nitrite levels progressively decrease with increasing cardiovascular
risk.257
In addition to the oxidation of NO, nitrite is also derived from reduction of
salivary nitrate by commensal bacteria in the mouth and gastrointestinal tract
246,247as well as from nitrite rich 240 diet.  Since a substantial portion of nitrite in
blood and tissue are derived from dietary sources 240, modulation of nitrite and/or
nitrate intake may provide a first line of defense for conditions associated with NO
insufficiency 245. The primary dietary sources of nitrates and nitrites include plants,
vegetables and a few fruits, nuts,  processed and cured meat, fish and poultry and
drinking water, to which nitrites have been added. Plant foods are the primary
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sources of nitrate, while processed and cured meats are the primary sources
of nitrites 258
Since the NO• radical is rapidly metabolized into the stable end-products
nitrite and nitrate, determination of nitrite and nitrate does not demonstrate ongoing
NO• production. Considering that the half-life of  nitrate  in  plasma  is  ~5  h 195,
increased concentrations of nitrate in plasma after overnight fasting at least indicate
recent NO• production. The most commonly used nitrite assay is based on the Griess
diazotization reaction, which is specific for nitrite and does not detect nitrate.
Therefore, nitrate in samples must first be reduced to nitrite; subsequent nitrite
determination thus yields the total nitrite + nitrate concentration of the sample (
NOx)
Various studies on plasma NOx assay203:
 (a)  recovery of nitrite and nitrate from plasma is near-quantitative (87%) and
reproducible.
 (b)  nitrite and nitrate are stable in (frozen) plasma for at least 1 year.
 (c) nitrite in whole blood is very rapidly (> 95% in 1 h) oxidized to nitrate, and
therefore plasma nitrite determination alone is meaningless.
(e)  plasma nitrite and nitrate concentrations were not correlated (nitrite as % of
total nitrite + nitrate varied from 3.9% to 88% in plasma samples).
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(f)  plasma samples should be de-proteinized, and background controls should be
included in the assay, to avoid measuring the falsely  high nitrite and nitrate
concentrations in plasma.
b. S-NITROSOTHIOLS :
S-nitrosothiols are thio-esters of nitrite, with the general structure R-S-N=O;
naturally occurring examples include S-nitrosocysteine, S-nitrosoglutathione and S-
nitrosoalbumin, in which R is an amino acid, polypeptide and protein respectively.
Reactive protein thiols are  regarded as major intracellular target of NO. Nitrite is in
steady state of equilibrium  with S-nitrosothiols .
S-nitrosation has since been implicated in the control of a wide array of
protein functions and cell activities like,  regulation of apoptosis, G-protein-coupled
receptor based signaling, vascular tone and inflammatory responses 262-265. Among
the growing list of proteins whose activities are regulated by s-nitrosation some are,
ion channel proteins, kinases, proteolytic enzymes, transcription factors and proteins
involved in energy transduction 259. Dysregulation of protein S-nitrosation is
associated with a growing list of pathophysiological conditions 259and altered blood
levels of RSNO have been associated with impaired clinical outcome in patients
with cardiovascular disease260,261.
     S-nitrosoglutathione reductase  (GSNOR), a member of alcohol
dehydrogenase family, has been shown to be the primary pathway through which
cells denitrosate intracellular proteins 266. GSNOR has become an important target
for developing agents that modulate NO bioactivity inside the cells.
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3.  NITROTYROSINE :
NO reacts with superoxide anion to form peroxynitrite, that can further form
peroxynitrous acid, a very unstable and reactive oxidizing species. Involvement of
ONOO is the most widely studied mechanism of protein nitration 267 . The formation
of nitrotyrosine has been detected in various pathological conditions including
atherosclerosis, myocardial infarction, hypertension, myocarditis, heart failure,
shock, diabetic complication and neurodegenerative and inflammatory disorders 268.
            Substantial evidence has emerged which revealed a very close association
between the formation of nitro-tyrosine and the presence of activated granulocytes
containing peroxidases, such as MPO 269-272. MPO-generated reactive species
participate in the induction of foam cell formation, endothelial dysfunction, and
development of vulnerable plaque. Carr and Frei have revealed that,  physiological
concentrations of nitrite inhibit MPO mediated modification of LDL273providing a
means to interrupt the process. These data also demonstrate the first line of evidence
of nitrite acting in an "antioxidant" capacity in atherosclerosis.. This may represent a
novel mechanism by which metabolites of NO may exert an anti-atherogenic effect .
REDUCED NITRIC OXIDE IS NOT DUE TO SUBSTRATE296 :
In normal humans, availability of substrate for production of No, is a rate-
limiting step for endothelium-dependent vascular relaxation. In contrast, increased
availability of NO precursor does not modify endothelium-mediated vasodilation in
hypertensives. These findings provide evidence of a defect in the endothelium-
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derived  NO system in hypertension and indicate that, this abnormality is not related
to decreased availability of substrate for NO production.
SUPEROXIDE PRODUCTION AS A CAUSE OF NITRIC OXIDE-
DEFICIENT HYPERTENSION :  ( Figure : 9 )
One of the principal mechanisms of endothelial cell dysfunction in
hypertension, is the production of superoxide anion and other reactive oxygen
species that quench NO, thereby reducing its bioavailability63. There are three main
enzymatic sources of vascular superoxide:
 (1) Reduced form of NADPH oxidases, The activity of NAD(P)H oxidases
is increased by physical stress (eg, increased blood pressure), cytokines and
angiotensin II220. There is increasing experimental evidence that, generation of
superoxide anion by NAD(P)H oxidases is a major mechanism by which, minimal
elevations in plasma renin and angiotensin II levels lead to sustained elevations in
blood pressure288 . The reduced generation of superoxide and restoration of
endothelial-dependent vasodilation appears to be an important mechanism mediating
the anti-hypertensive and cardioprotective effects of ACE  inhibitors and
angiotensin-receptor blockers289-290.
(2) NOS produces superoxide, only when an important cofactor
(tetrahydrobiopterin) is deficient (a process known as NOS uncoupling).
 (3) Xanthine oxidase, that produces uric acid76. Generation of reactive
oxygen species by xanthine oxidase accounts for the association of elevated serum
uric acid levels with endothelial dysfunction and essential hypertension77. However,
Figure : 8
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uric acid is an antioxidant too. Thus, the xanthine oxidase inhibitor allopurinol, does
not consistently lower blood pressure in patients with hypertension, as the drug
simultaneously reduces both these opposing effects on vascular function78.
 Experimental studies suggest that the antioxidant agents may re-establish
endothelial function64,65. Vitamin C, a potent antioxidant in vivo and in vitro 66
inhibits superoxide-mediated lipid peroxidation67 and improves endothelial function
in  smokers70 as well as in patients with coronary artery disease68 and diabetes
mellitus69. Superoxide dismutases are enzymes produced in blood vessels that
normally inactivate superoxide. In rats, hypertension produced with infusion of
angiotensin-II, was reversed when  superoxide dismutase was delivered in
membrane-permeable liposomes289. Increased antioxidant production with improved
endothelial-dependent vasodilation is likely to be a potential mechanism, underlying
the mild antihypertensive effect of regular aerobic exercise293.
DECREASED NOS EXPRESSION AS A CAUSE OF HYPERTENSION 294 :
The eNOS knockout mouse develops mild-to-moderate hypertension, with
basal blood pressure levels typically 20 mm Hg higher than in control littermates276.
When normotensive mice were engineered to express the constitutively active eNOS
in excess, their mean blood pressure levels were 18 mm Hg lower than normal278. In
spontaneously hypertensive rats, a single intravenous injection of human
complementary DNA encoding eNOS almost completely normalized blood pressure
for 5 to 6 weeks279.
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ENDOGENOUS NOS INHIBITORS AS A CAUSE OF HYPERTENSION :
An increase in endogenous inhibitors of nitric oxide synthesis, may be
involved in the genesis of endothelial dysfunction. In normotensive animals and
humans,  administration of methylated arginines, which are competitive NOS
inhibitors276-277, caused marked and dose-dependent elevations in blood pressure
level.
Asymmetric dimethyl arginine (ADMA) and symmetric dimethyl arginine
are endogenous substances first isolated from human plasma and urine. When
infused into the human brachial artery, ADMA causes vasoconstriction whereas
symmetric dimethyl arginine is inert284. Because ADMA is normally cleared by the
kidney, the plasma concentration increases 3- to 10-fold in humans and animals with
renal failure285. It competes with L-arginine to prevent the synthesis of  nitric oxide
71. Thus, accumulation of this endogenous NOS inhibitor has been hypothesized to
contribute to hypertension in patients with chronic renal failure287(but not yet
proven).  Studies have shown reduced urinary excretion of NO metabolites and
increased plasma levels of  ADMA in men with essential hypertension285.
NITRIC OXIDE SYNTHASES (NOSS, EC 1.14.13.39) :
The NOSs were first identified and described in 1989. The three major
isoforms were cloned and purified between 1991 and 1994. The first X-ray crystal
structures of NOS domains have been presented and published in 1998 and 1999
(Figure : 10 ) .
Figure : 10
X-RAY CRYSTALLOGRAPHIC STRUCTURE OF ENDOTHELIAL
NITRIC OXIDE SYNTHASE
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Three quite distinct isoforms of NOS have been identified as products of
different genes, with different localization, regulation, catalytic properties, inhibitor
sensitivity and with 51–57% homology between the human isoforms. These
isoforms will be referred to, by the most common nomenclature , based on the order
in which they were first purified and cloned.
? nNOS (also known as Type I, NOS-I and NOS-1) being the isoform
first found (and predominating) in neuronal tissue
? iNOS (also known as Type II, NOS-II and NOS-2) being the isoform
which is inducible in a wide range of cells and tissues
?  eNOS  (also  known  as  Type  III,  NOS-III  and  NOS-3)  being  the
isoform first found in vascular endothelial cells
In the past, these isoforms have also been differentiated on the basis of their
constitutive  (eNOS  and  nNOS)  versus  inducible  (iNOS)  expression  and  their
calcium-dependence (eNOS and nNOS) or independence (iNOS).
STRUCTURE : ( Figure : 11 )
NOS exhibit a bi-domain structure, in which an N-terminal oxygenase
domain containing binding sites for heme, BH4 and L-arginine, is linked by a
calmodulin-recognition site to a C-terminal reductase domain,  containing binding
sites for FAD, FMN and NADPH 83-85.  The  known  NOS  enzymes  are  usually
referred to as 'dimeric' in their active form, ignoring the required calmodulins
(CaMs)  which,  strictly  speaking,  mean they  are  tetramers  (of  two NOS monomers
Figure : 11
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associated  with  two  CaMs).  They  contain  relatively  tightly  bound  cofactors  BH4,
FAD, FMN and heme.
NOS dimerization:
The association of the NOS into active dimers, involves a large interface in
the oxygenase domain,  involving two sections of the primary structure of NOS
86,87,89 . This  interface includes the binding site for BH4 and helps to structure the
active-site pocket containing the heme and the L-arginine binding site; it has two
cysteine residues per monomer, which either forms a disulphide bridge between the
monomers or  ligates a zinc ion between the monomers 88,89. Furthermore, there is an
'N-terminal hook' domain, which swaps between the two monomers, to stabilize the
dimer 89.  BH4  as  well  as  heme  and  L-arginine   promote  and  stabilize  the  active
dimeric form of all the three isoforms. The presence of heme appears to be
mandatory, with BH4 and L-arginine promoting dimer formation and stabilization.
The flow of electrons from reductase domain of one monomer,  to the oxygenase
domain of the other monomer  forms NO, as shown in Figure: 12.
Endothelial cell constitutive nitric oxide synthase can be activated by stimuli
that include thrombin, adenosine diphosphate, bradykinin, substance P, muscarinic
agonists, catecholamines, and shear stress 121.
REGULATION OF NOS :
CALMODULIN:
Calmodulin  was  the first protein shown to interact with NOS90 and is
necessary for the enzymatic activity of  the three isoforms. CaM binding increases
Figure 12 :
ELECTRON FLOW IN eNOS
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the rate of electron transfer from NADPH to the reductase domain flavins 91,92and
from the reductase domain to the heme centre 93.
PHOSPHORYLATION:
Phosphorylation  of  the  nNOS  and  eNOS  isoforms  has  an  effect  on  NOS
activity. Fluid shear stress elicits phosphorylation of eNOS and an increase in its
activity 94,95. Studies showed that Ser1179 of eNOS is phosphorylated by protein
kinase 96,97, which results in an increase in electron flux through the reductase
domain and an increase in NO production 98.
HEAT-SHOCK PROTEIN 90 (hsp90):
The molecular chaperone hsp90 has been identified as a regulator of eNOS
activity, possibly as an allosteric modulator 103. Activation by vascular endothelial
growth factor, histamine or fluid shear stress in human endothelial cells increases the
interaction between eNOS and hsp90 and increases eNOS activity by approximately
three-folds. . Kallikrein appears to inhibit iNOS by preventing the formation of
iNOS dimers 104 and may play a neuroprotective role during inflammation.
REGULATION OF eNOS LOCALISATION: ( Figure : 13 a & b)
MYRISTOYLATION and PALMITOYLATION :
Of the three NOS isoforms, only eNOS is acylated by both myristate and
palmitate 105. eNOS is co-translationally and irreversibly myristoylated at an N-
terminal glycine residue while palmitoylation occurs post-translationally and
reversibly at cysteine residues (Cys15 and Cys26). Dual acylation of eNOS is required
Figure : 13a
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for efficient localization to the plasmalemmal caveolae of endothelial cells 108.
Palmitoylation109 is dynamically regulated by  bradykinin -induced changes in
intracellular Ca2+.
CAVEOLIN :
eNOS is localized to the caveolae108,110 , which are microdomains of the
plasmalemmal membrane that are implicated in a variety of cellular functions
including signal transduction events. Vascular  eNOS binds to caveolin-1, while in
cardiac myocytes , eNOS is associated with caveolin-3 111. Caveolin-1 and peptides
from the ‘caveolin-1 scaffold region’ directly inhibit eNOS activity and this
interaction is regulated by Ca2+/CaM 112,113. Caveolin-3 binds to nNOS in the
skeletal muscle, inhibiting NO synthesis and this inhibition is reversed by Ca2+/CaM
114.
MITOCHONDRIAL NOS :
There have been some suggestions in recent years that, there might be a NOS
in mitochondria. This was originally based on cytochemical and immuno-
cytochemical evidence 116-118 , showing association of either NADPH diaphorase or
NOS antibody-binding to mitochondrial membranes. This NOS seems likely to
consist of a membrane-associated iNOS115. Although iNOS does not have fatty
acylation sites like those of eNOS, membrane association via binding to membrane
proteins such as the caveolins provide a plausible alternative mechanism for this.
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PHYSIOLOGICAL ROLE OF NOS:
? Under normal physiological conditions, iNOS is not detectable in
macrophages and other tissues, and thus appears to play little if any role in
the normally functioning cardiovascular system. However, induction of
iNOS expression by cytokines or inflammatory mediators is thought to play
a pivotal role in causing hypotension during septic shock.
?  In contrast, both eNOS and nNOS are constitutively expressed and are
thought to contribute to the normal regulation of vasomotor tone and blood
pressure119. eNOS derived NO was considered to be the most important
regulator of vasomotor tone120.
eNOS AND VASOMOTOR TONE :
In the vascular endothelium, agonists such as acetylcholine and bradykinin
stimulate inositol 1,4,5-triphosphate ( IP3 ) production, the second messenger
system. IP3 binds to receptors on the endoplasmic reticulum and causes Ca2+ release
from intracellular stores 122. This transient elevation of intracellular Ca2+ promotes
calcium binding to calmodulin, forming a complex that is a crucial cofactor for
constitutive NOS activity 123.  eNOS  produces  modest  amounts  of  NO  until  the
calcium  concentration  decreases.  This  rapid  and  transient  production  of  NO  by
eNOS allows NO to function in maintaining basal vascular tone 122.
eNOS  GENE  :
Given  the  pivotal  role  of  eNOS  in  vascular  homeostasis,  the  eNOS  gene
(NOS3) has emerged as a logical candidate gene in the investigation of hypertension
genetics 126.
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Animal models of altered eNOS gene expression have emphasized the
crucial role of this enzyme in a diverse array of vascular biology and pathology.
Among others, eNOS-/- (knock  out)  mice  have  been  associated  with  systemic  and
pulmonary hypertension124-126, altered vascular remodeling127,128 , impaired
angiogenesis129,130 and perturbations in homeostasis. A decrease in eNOS protein
expression was also observed  by immunohistochemistry131 . This down-regulation
of eNOS mRNA, undoubtedly, contributes to the reduced endothelial NO production
and defective endothelium-dependent vasorelaxation133 observed in diseased
atherosclerotic vessel.  It is now appreciated that decreased endothelial eNOS
mRNA and protein can be observed in diseased human blood vessels .
NOS3 gene is located in the chromosome 7 , corresponding to the 7q35-q36
region, contains 26 exons with an entire length of 21kb. ( Figure :14 )
REGULATION OF eNOS GENE EXPRESSION :
Numerous exogenous stimuli and conditions that are relevant to the
pathology of vascular endothelium have been shown to alter eNOS expression
through the modulation of steady-state eNOS mRNA 134. This regulation occurs at
both the transcriptional and posttranscriptional levels.
TRANSCRIPTIONAL REGULATION:
eNOS CORE PROMOTER:
The eNOS gene encodes a mRNA of 4052 nucleotides and is present as a
single copy in the haploid human genome. Sequence inspection of 5'-flanking
regions revealed multiple potential cis-regulatory DNA sequences in the setting of a
Figure : 14
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Figure : 15
VARIOUS POLYMORPHISMS OF eNOS
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"TATA-less" promoter: Sp1, GATA, AP-1, NF-1, shear-stress response elements,
and sterol-regulatory elements135. There are two tightly clustered cis-positive
regulatory elements in the proximal core promoter of the human eNOS gene.
Positive regulatory domain I (PRD I; -104 to -95 relative to transcription initiation)
was mapped to a 10-bp cis-region corresponding to a high-affinity Sp1 transcription
factor recognition site. PRD II (-144 to -115) encompassed a 30-bp region of the
core promoter and formed nucleoprotein complexes containing the transcription
factors Elf-1, YY1, Sp1, and MAZ136. Expression studies in Drosophila SL2 cells
revealed that functional interactions between these trans-acting factors are critical
for eNOS promoter activation. Mutating cis-elements in PRD I or PRD II disrupted
co-operative activation of the human promoter136 .
CELL SPECIFIC EXPRESION :
eNOS gene expression is relatively restricted to the vascular endothelium134.
The existence of a distal enhancer element  has the ability to direct the appropriate
cell-specific expression pattern of the eNOS gene. The human eNOS proximal
promoter was differentially methylated in expressing and non-expressing cell
types137. In non-expressing cells, the core promoter CpG di-nucleotides were densely
methylated, whereas in eNOS-expressing endothelial cells they were non-
methylated. Differential promoter methylation was further implicated in the
determination of cell-specific eNOS expression, by the successful induction of
endogenous eNOS mRNA expression in non-expressing cell types. This may occur
in response to de-methylation by 5-azacytidine, a DNA methyltransferase inhibitor.
It has been suggested that promoter methylation down-regulates transcription by
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recruitment of methyl-CpG binding proteins and histone de-acetylase activity,
resulting in a closed and transcriptionally repressive chromatin structure138 .
SHEAR STRESS :
The effect of changes in blood flow on eNOS expression has been an
important focus of investigation139.  Animal  studies  emphasized  the  role  of  the
endothelium in exercise and flow induced vasodilation, which showed an up-
regulation of eNOS expression140,141 . Indeed, eNOS-/- mice  were  found  to  be
incapable of vascular remodeling, in response to shear stress127. At the molecular
level, shear stress was found to induce eNOS mRNA expression via a transcriptional
pathway142 .
TRANSFORMING GROWTH FACTOR (TGF-?1) :
TGF-?1 is increasingly recognized as an important mediator in vascular
immune injury, vessel remodeling, vasculogenesis and angiogenesis143,144. TGF-?1
has been shown to increase bovine aortic endothelial cell (BAEC) and human
umbilical vein endothelial cell (HUVEC) steady-state eNOS mRNA expression in a
concentration-dependent manner145,146 .  The TGF- ? response element was mapped
to  a  NF-1 cis-DNA binding site, a region spanning -1000/-720 of the human
promoter. TGF?1 transactivates the  eNOS  promoter  via  recruitment  of
ribonucleoprotein (RNP) complexes containing SMAD2 and NF-1 at distinct sites.
CYCLOSPORINE A :
Immunosuppressive therapy with cyclosporine A has been commonly
associated with hypertension, with its effects attributed to paracrine vasoconstrictors.
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It was also found to augment NO production paradoxically in vitro and in vivo.
Cyclosporin A treatment of endothelial cells in culture was shown to enhance eNOS
expression through transcriptional activation147,148 .
POST TRANSCRIPTIONAL  REGULATION :
TUMOR NECROSING FACTOR (TNF- ) :
TNF-  has been shown to reduce endothelium-dependent vaso-relaxation in
vivo and ex vivo151,152.  Some  of  the  studies  of  eNOS gene regulation, identified
modulation of mRNA stability as a regulatory target of pro-inflammatory
cytokines151,154 . Indeed, TNF-  alone reduced the half-life of eNOS mRNA from 48
hours to 3 hours149 .
DUAL REGULATION:
TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL EFFECTS:
OXIDIZED LOW-DENSITY LIPOPROTEINS :
Liao et al first reported that, oxidized low-density lipoproteins (ox-LDL)
caused a time and concentration-dependent decrease in steady-state eNOS mRNA
and enzyme activity in human endothelial cells155. This down-regulation was found
to occur principally at the post-transcriptional level, resulting in a reduction in eNOS
mRNA half-life from 36 to 10 hours. Low concentrations of  ox-LDL  ( 10 µg
protein/mL) may be associated with a paradoxical increase in eNOS mRNA and
protein expression156 . Very high levels of native LDL were found to decrease eNOS
mRNA expression157. Lysophosphatidyl choline, a major component of ox-LDL, can
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increase eNOS mRNA in  BAEC156. Perhaps this provides an explanation for the
biphasic effect of varying doses of ox-LDL.
3-HYDROXY-3-METHYLGLUTARYL-COENZYME A (HMG-CoA) REDUCTASE
INHIBITORS (STATINS):
The mechanisms, by which statins confer lipid-independent cardiovascular
protection, have stimulated substantial interest. Much focus has centered on the
vasoactive and angiogenic properties of statins and the possible role of eNOS in
mediating such effects158. Treatment of eNOS-/- mice with statins did not result in
protection from ischemic injury.
Statins have been shown to prevent the down-regulation of eNOS mRNA by
ox-LDL159,160 , hypoxia and TNF- 150. Indeed, HMG-CoA reductase inhibition has
been associated with increased eNOS expression in human endothelial cells by the
prolongation of its already-long mRNA half-life159,161 .  A  noted  prolongation  of
eNOS transcript half-life was consistent with the observed 3-fold increase in steady-
state eNOS mRNA levels after 24 hours of statin exposure.
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) :
As the important role of VEGF in blood vessel development, endothelial
biology and vascular disease continues to be revealed162 , the relationship between
VEGF and eNOS/NO becomes increasingly defined. For instance, using a murine
ischemic limb model, Murohara et al found that VEGF failed to improve
angiogenesis in eNOS-/- mice, suggesting that eNOS was a downstream mediator of
VEGF-induced angiogenesis129 . At the molecular level, Bouloumie et al showed
that VEGF165 increased steady-state eNOS mRNA expression in HUVEC in a time
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and concentration-dependent manner163 . Transcription arrest studies attributed this
enhanced expression to a significant increase in eNOS mRNA stability.
HYPOXIA :
Hypoxia has been associated with both the up-regulation and down-
regulation of  steady-state  eNOS mRNA expression.  Given,  that  the  body regularly
deals with a wide range of oxygen tensions based on the demands of specific organs,
it is not surprising that endothelial cells from various vascular beds should respond
to hypoxia differently, depending on the specific in vivo and in vitro milieus, as well
as the chronicity and severity of the hypoxic exposure164-168 .
The histone de-acetylase inhibitor, trichostatin A(TSA)  is known to inhibit
angiogenesis in response to VEGF and hypoxia169,170. Recently, in studies designed
to elucidate the mechanism of this inhibition, Rossig et al discovered that TSA
treatment of HUVEC markedly decreases steady-state levels of eNOS mRNA,
without affecting transcription rate as measured by nuclear run-off171 .  TSA
treatment increased eNOS promoter–reporter activity. Taken together, these data
suggest that TSA modulates eNOS mRNA expression via a post-transcriptional
mechanism.
eNOS GENE POLYMORPHISM :
 Variants of the NOS3 gene located in the 7q35-q36 region, contains 26
exons with an entire length of 21kb have been investigated for association with
hypertension and other cardiovascular disorders 172. Of these, three polymorphisms
have been widely examined for clinical relevance, based on their potential functional
effects and their relatively high minor allele frequency in various ethnic
groups172,173. ( Figure 15 )
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(i) a G894T substitution in exon7 resulting in a Glu to Asp substitution
at codon 298 (rs1799983).
(ii)  an insertion-deletion in intron4 (4a/b) consisting of two alleles (the
a-deletion which has four tandem 27-bp repeats and the b-insertion
having five repeats).
(iii)   a T786C substitution in the promoter region (rs2070744).
Several polymorphisms of eNOS gene  are  found  to  be  associated  with
increased risk for cardiovascular disease. Of these 894 G greater than T variant in
exon 7 is reported to be associated with cardiovascular disease 308 while 786 T
greater than C polymorphism has been associated with hypertension310 and with
coronary spasm. 311A 27 bp VNTR located in intron4 of eNOS gene was proven to
be of equal interest. It was demonstrated that 27bp repeat in the eNOS gene could
bind nuclear proteins as an enhancer/repressor to promote/suppress the
transcription efficiency.  Functional significance of this polymorphism was also
identified in cases with endothelial dysfunction.  Wang et al312 reported a significant
association of this intron with CAD. Other studies on eNOS intron4 polymorphism
showed positive association with renal disease 313,314 , essential hypertension among
Japanese 315 and stroke among Chinese 316 . However, studies from Taiwan 317 did not
reveal any association with premature CAD. The discrepancy in these studies on the
association of eNOS intron 4b/a VNTR polymorphism with essential hypertension
may be related to ethnic diversity. Hence, we investigated this polymorphism in the
patients  attending  the  hypertension  clinic  to  find  the  extent  of  risk  caused  by  this
gene, if any.
AIM OF THE STUDY
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AIMS AND OBJECTIVES
Endothelial dysfunction is considered as the cornerstone in the pathogenesis
of essential hypertension. Nitric oxide , the second messenger is found to be the
main factor involved in endothelial dysfunction and its level is found to be altered in
hypertensive states. As the eNOS is the major enzyme responsible for nitric oxide
production, variation in its expression and activity can be linked to hypertension.
In this study, the aim is to elucidate the association between the intron4a/b
polymorphism in NOS3gene with NO levels and essential hypertension. The specific
objectives were :
1.   To  study  the  levels  of  NO  in  the  serum  of  patients  with  essential
hypertension and controls
2.  To determine the genotype frequencies of the eNOS intron4 VNTR
polymorphism in the extracted DNA of the patients with essential
hypertension and controls.
3.  To determine if there is any correlation between these polymorphisms and
essential hypertension.







STUDY DESIGN : case- control study.
STUDY POPULATION :
CASES :
           The study sample is comprised of 150 unrelated essential hypertensive
patients  attending  the  outpatient  hypertension  clinic  in  Govt.  General  Hospital  ,
Chennai, which included 131 males and 19 females,  of mean age 50.59 + 10.52
years.
Inclusion criteria :
Hypertensives, on treatment for 5 – 10 years.
Exclusion criteria :
1. secondary hypertension




6. chronic inflammatory states
7. drugs – oral contraceptive pills , steroids
8.  chronic smokers.
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CONTROL SUBJECTS :
130 apparently healthy normotensive controls were taken up from the out-
patient department, during their visit for master health check up and minor health
ailments. Confounding factors like age, sex, smoking, alcoholism were matched.
Exclusion criteria were the same as that of cases.
METHODS:
             Resting blood pressure was recorded in each subject, after a thirty minutes
rest on a couch. Height and weight were recorded and blood samples were collected
by venipuncture after an overnight fasting in two test tubes.
1.  2 mL of sample taken in EDTA-NaF tube was centrifuged at 2000 rpm for
twenty minutes. The buffy coat was used for DNA extraction and plasma
for glucose estimation.
2.  3 mL of blood was taken in a plain tube, centrifuged at 2000 rpm for 20
minutes and serum was placed in two aliquots –
a. for estimating lipid profile, serum urea & creatinine
b. for serum NOx estimation.
BIOCHEMICAL MARKERS:
Plasma glucose , serum urea , serum creatintine were estimated. Total
cholesterol (TC), high density lipoprotein cholesterol (HDL-c) and triglyceride
concentration (TGL) were determined enzymatically using kits and XL-300 auto
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analyzer at Centralized Biochemistry Laboratory at G.G.H, Chennai-3. Low density
lipoprotein cholesterol (LDL-c) was calculated using Friedwald’s formula304. Serum
NOx estimated by Griess method
DNA EXTRACTION BY MODIFIED HIGH SALT METHOD305
RBC Lysis :
? 400µL of buffy coat in a 2mL eppendorf was mixed with 1.6mL of 0.17M
ammonium chloride and mixed by inversion for about 10 minutes, until red
cells were lysed.
?  The cells were then centrifuged at 4000rpm for 10 minutes.
? The white cell pellet was washed with 800µL of 0.17M ammonium chloride
solution.The procedure was repeated till a clear white cell pellet was
obtained.
WBC Lysis :
? To the  pellet  500  µL of  TKM I*  solution  was  added.  It  was  centrifuged  at
10,000 rpm for 10minutes.
Nuclear Lysis :
? The supernatant was discarded and 500 µL of TKM II* solution was added
to the pellet.  300 µL of 6M Nacl and 50 µL of 10% SDS was then added.
? Mixed well in a vortex and centrifuged at 10,000 rpm for 10 minutes.
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? The supernatant was transferred to a 1.5mL eppendorf.
* TKM-I solution contains 10mM  TRIS HCl,10mM  KCl,10mM  MgCl2 & 2mM EDTA
   TKM-II solution contains 10mM TRIS HCl , 10mM  KCl, 10 mM  MgCl2,  2mM
    EDTA and  0.4 M Nacl
DNA Precipitation :
? To the supernatant double the volume of 100% ethanol was added.
? The sample was stored at -20?C for 1 hour.
? It was then centrifuged at 10,000 rpm for 20minutes at 4?C in a refrigerated
centrifuge.
? The supernatant was discarded and 500 µL of 70% ethanol was added to the
pellet. It was  mixed and centrifuged at 10,000 rpm for 10 minutes at 4?C.
? Supernatant was discarded and the pellet was air dried.
Storage :
? To the  pellet  30  µL of  LTE buffer  was  added  and  the  extracted  DNA was
stored at -20?C for future use.
Identification :
? Extracted DNA was identified following an electrophoretic run using 0.8%
agarose  with  a  constant  voltage  of  7V/  cm along  with  a  comparison  with  a
known molecular weight 1kb DNA ladder. (Figure: 17 )
Figure 17 :
GEL DOCUMENTATION OF EXTRACTED DNA :
Figure 18 :
ELECTROPHORETOGRAM OF PCR PRODUCTS





1        2       3      4        5       6      7       8
Lane 6 -  aa genotype
Lane 2,7 – ab genotype
Lane 1,3,4,5 – bb genotype
Lane 8 – 100 bp DNA ladder
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POLYMERASE CHAIN REACTION
? eNOS gene was amplified using,
• Forward primer – 5?-AGGCCCTATGGTAGAGCCTT-3? and
• Reverse primer –  5?-TCTCTTAGTGCTGTGGTCAC-3?
PRIMER RECONSTITUTION:
Primers were supplied in lyophilized form. Autoclaved distilled water was
used to prepare 100x concentrations i.e., 10 times the molecular weight of primer
was the volume of water required to prepare 100x concentrations which was 100
µmolar solution.
? From this stock solution 10x concentration was prepared as the working
solution for PCR.
MASTER MIX:
? Master Mix consists of a unique inert red dye in addition to basic
components necessary for PCR.
? Red Dye master mix was used in the following composition :
• Reaction buffer consisted of Tris Hcl -10 mM, at pH- 8.3, KCl – 50 mM.
• MgCl2 - 1.5 mM acts as catalyst.
• dNTP’s were used in a concentration of 2.5 mM each.
• Taq polymerase in a concentration of 1.5 U.
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? Primers were used in a concentration of 5 pmol and DNA was used in a
concentration of 200 ng.
? PCR  was  carried  out  in  a  reaction  volume  of  25  µL  with  the  following
components;
• PCR master mix – 12.5 µL
• Forward primer – 0.9 µL
• Reverse primer – 0.9 µL
• DNA – 2 .0µL
• Distilled water – 8.7 µL
• Total – 25 µL
? Amplification was carried out in a thermal cycler with the following cycling
conditions.
Initial denaturation – 940 C -5min
30 cycles of :
- denaturation – 940C – 1 min
- annealing      - 540C – 1min
- extension      - 720C – 1min
Final extension at 720C - 10 min.
?  Amplified products  viz. 393 bp size for ‘a’ allele and 420 bp size product
for ‘b’ allele were identified by 3% agarose gel electrophoresis by
comparison  with  a  known  100bp  DNA  ladder.  Thus,  each  DNA  sample
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revealed one of three possible patterns after electrophoresis viz., a 393 bp
band (aa genotype), a 420 bp band (bb genotype) or both 393 and 420 bp
bands (ab genotype) ( Figure 18 ).
AGAROSE GEL ELECTROPHORESIS :
? PCR product was run on agarose gel in a 50 mL agarose cast as follows: 1.5g
of agarose was weighed and dissolved in 50mL of 1x TAE buffer** with a
pH of 8.0.
? It was heated in a microwave oven for 60 secs, cooled and 2.5 µL of
ethidium bromide (10mg/moL) was added. It was poured into a cast and
allowed to solidify for 15 min, freed of any air bubbles before it was kept in
the  electrophoresis  tank.  8  µL  of  PCR  product  was  loaded  onto  wells  in  a
consecutive manner and 4 µL of 100 bp DNA ladder was loaded in the last
well as a marker. After a run at 8V/cm for 45min,  it was visualized under
UV illumination.
** To  make  50x TAE buffer   ( 250 ml ) pH : 8.3
Triose base            : 60.5 gm
Glacial acetic acid : 14.27 mL
0.5 M EDTA         : 25 mL {pH adjusted to 8 with 10N NaOH  }
Make it up to 250 mL with distilled water
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MEASUREMENT OF SERUM NOx:
CADMIUM BASED REDUCTION OF NITRATE TO NITRITE FOLLOWED
BY GRIESS METHOD :
Principle :
In this method , cadmium, exposed to copper sulfate solution reduces Cu2+ to
form a porous metallic copper “ coat”. This copper facilitates electron transfer from
cadmium to nitrate, thereby reducing nitrate to nitrite. Cadmium has a reduction
potential of -0.403 V. On the other hand , redox potential of nitrate / nitrite is
dependent on pH ranging from 0.94 V in acidic solution to 0.015V in basic solution.
Therefore, reduction reaction of nitrate to nitrite by cadmium is thermodynamically
favourable.
Nitrite reacts with sulfanilamide in acidic media to form a transient
diazonium salt. N-naphthyl- ethylenediamine (NED)  converts this salt to a  stable
azo compound with intense purple color,  measured at 540 nm.
Procedure :
Step 1 :De-proteinisation306 :
             300 µL of serum by adding 250 µL of 75 mmol/L ZnSO4 solution, stirring ,
and centrifuging at 10 000g for 1 minute at room temperature, after which 350 µL of
55 mmol/L NaOH was added. Again , the solution was stirred and centrifuged at
10,000g for 3 minutes and the supernatant was recovered (free of turbidity ).  Then
diluted by mixing 750 µL of supernatant with 250 µL of glycine buffer (45 g/L,
pH 9.7).
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Step 2 : Activation of cadmium :
Cadmium granules  were rinsed three times, with deionized distilled water
and mixed in a shaker gently  in a 200 mmol/L copper sulfate307 solution in glycine-
NaOH buffer (15 g/L, pH 9.7) for 5 minutes till the color of the solution fades. The
solution was drained off and the step was repeated. The copper-coated granules dried
in tissue paper, should be  used within 10 minutes. After use, the granules were
rinsed and stored in 100 mmol/L H2SO4 solution;  they  can be regenerated by
repeating the steps.
Step 3 : Reduction of nitrate :
 The nitrite and nitrate calibrators were diluted with glycine buffer .
Calibration curves were made over a linear range of nitrite between 0 and 100
µmol/L. Freshly activated cadmium granules (2–2.5 g) were added to 1 mL of pre-
treated de-proteinized serum and calibrator. After continuous stirring for 10 minutes,
the samples were transferred to appropriately labeled tubes for nitrite determination.
Step 4 : Nitrite assay :
Nitrite was estimated by Griess method.
Reagent 1 :  50 mg of N-naphthylethylenediamine dissolved in 250 mL of distilled
water.
Reagent 2 : 5 g of sulfanilic acid in 500 mL of 3 mol/L HCl.
Both solutions are stable for one year at 4 °C.
From the above tubes 200 L of sample were placed into fresh glass tubes.
Then 800 L sulfanilic acid solution was mixed, followed by 750 L NED solution.
Graph  : 1





















After an incubation period of 10 minutes at room temperature, pink color was
developed and its absorbance  read at 545 nm within 60 min. The measured OD was
plotted on the standardization graph and concentration found out.( Graph : 1 )
PLASMA GLUCOSE ESTIMATION
Method : Glucose oxidase- peroxidase method
Principle :
Glucose + O2 + H2O         glucose oxidase                        gluconic acid + H2O2
H2O2 + phenol + 4 aminoantipyrine       peroxidase          quinoneimine dye +2H2O
The  concentration  of  glucose  present  in  the  sample,  directly  propotional  to  the
intensity of pink colour developed , was measured at 540 nm.
Reagents :
Reagent 1 : glucose reagent
Glucose oxidase 20000 IU/L
Peroxidase 3250 IU/L
4-aminoantipyrine 0.52 mmol/L
4-hydroxybenzoic acid 10 mmol/L
Phosphate buffer 110 mmol/L
Standard :  glucose 100 mg/dL
Procedure :To 1  mL of  reagent,  10  µL sample  was  added  and  reading  was  taken
after an incubation period of 15 mins .
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Reference value :
Fasting glucose – 70 -  100 mg/dL
Post prandial – upto 140 mg/dL
 ESTIMATION OF UREA :
Method : UREASE- GLDH
Principle :
Urea  + H2O        urease                2NH4 + Co2
NH4 + NADH + 2-oxoglutarate   GLDH glutamate +  NAD+
The initial rate of decrease in absorbance at 340nm is propotional to the urea
concentration in the sample  .
Reagents :
R1 :     ?-ketoglutaric acid 99.8 mmml/L
Urease 23.5 KU/L
GLDH 3.5 KU/L
Adenosine diphosphate 7.6 mmol/L
Sodium azide 0.1%
R2 :     NADH 2.95 mmol/L
Sodium azide  0.1 %
Working reagent was prepared by mixing R1 & R2 in the ratio of 4:1.
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Procedure : To 1 mL of working reagent, 10µL of sample added, and  absorbance
read at 340 nm after  30 sec and 90 sec.
Reference value: 15 – 40 mg/dL
ESTIMATION OF SERUM CREATININE :
Method: Jaffe’s   method (initial rate)
Principle :
Creatinine reacts with alkaline picrate to produce an orange- yellow colored
creatinine picrate. The intensity of color was directly propotional to the
concentration of creatinine, which was measured in a photometric colorimeter at
500-520 nm.
Reagents :
Reagent 1 : Picric acid 25.8 mmol/L
Reagent 2 :Sodium hydroxide 95 mmol/L
Creatinine standard ( 2 mg/L)
Procedure : To 1 mL of reagent, 100 µL of sample added and the color  intensity
was  measured at 505 nm.
Reference range :
Males : 0.7 – 1.4 mg/dL
Females : 0.6 – 1.2 mg / dL
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LIPID PROFILE
The biochemical parameters undertaken for the study were determined using
the following methodologies:
ESTIMATION OF PLASMA TOTAL CHOLESTEROL
Method Cholesterol esterase – cholesterol oxidase
Principle
             cholesterol esterase
Cholesterol ester + H2O      cholesterol+ fatty acids
             cholesterol oxidase
Cholesterol + O2      cholestenone + H2O2
                peroxidase
H2O2 + phenol + 4- aminoantipyrine                  red quinine + 4H2O
The concentration of cholesterol in the sample, directly proportional to the
intensity of the red complex (red quinone), was measured at 500nm.
REAGENTS
Reagent 1 (enzymes / chromogen)
Cholesterol esterase ? 200U/L
Cholesterol oxidase ? 250U/L
Peroxidase ? 1000 U/L
4- aminoantipyrine  0.5 mmol/L
Reagent 1A (Buffer)
Pipes buffer, pH 6.90 50mmol/L
Phenol 25mmol/L
Sodium cholate 0.5 mmol/L
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Standard   : Cholesterol 200mg/dL
Procedure : To 1  mL of  the  reconstituted  reagent,  10  µL of  plasma is  added  and
reading is taken after 5 mins of incubation at 37o C.
Reference Values : 150 - 200 mg /dL
ESTIMATION OF PLASMA TRIGLYCERIDE
Method : Enzymatic / colorimetric method
Principle
Triglyceride + H2O lipoprotein lipase         glycerol + fatty acid
Glycerol + ATP glycerol kinase glycerol -3- phosphate + ADP
     glycerol -3- phosphate oxidase
Glycerol -3- phosphate                   dihydroxy acetone
              phosphate + H2O2
 peroxidase
2 H2O2 + 4 aminoantipyrine + ADPS red quinone + H2O
The intensity of purple colored complex formed during the reaction, directly
proportional to the triglyceride concentration in the sample, was measured at 546nm.
REAGENTS
Reagent 1 ( enzymes / chromogen )
Lipoprotein lipase ? 1100U/L
Glycerol kinase ? 800U/L
Glycerol -3- phosphate oxidase ? 5000 U/L
Peroxidase ? 350 U/L




Pipes buffer. pH 7.50 mmol/L
ADPS 1mmol/L
Magnesium salt 15 mmol/L
Standard  : Triglycerides 200mg / dL
Procedure : To  1  mL of  the  reconstituted  reagent,  10  µL of  plasma is  added  and
read at 546nm after incubation at 37oC for 5mins.
Reference ranges : less than  150 mg/dL




Chylomicrons, VLDL, and LDL fractions in plasma are separated from HDL
by immune-inhibition. Anti human ?-lipoprotein antibody  in reagent 1, binds to
lipoproteins (Chylomicrons, VLDL, and LDL) other than HDL. The antigen-
antibody complexes formed block enzyme reactions when reagent 2 is added.
Cholesterol esterase and cholesterol oxidase in reagent 2 react, only with HDL-C.
Hydrogen peroxide produced by enzyme reactions with HDL-C, yields a blue
coloured complex upon oxidase condensation with F-DAOS and 4-aminoantipyrine
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(4-AA)  in  the  presence  of  peroxidase  .  The  intensity  of  the  blue  color  complex
formed at 593 nm was proportional to the HDL-C in the sample.
 anti-lipoprotein B antibody
LDL, VLDL & chylomicrons         antigen antibody complex
        CHE & CO
HDL-C + H2O +O2 4-cholestenone + fatty acid + H2O2
       peroxidase
H2O2 + DAOS + 4AAP blue colored complex + 2H2O
REAGENTS :
Reagent 1 :
Goods buffer pH 7.0 ; 30.0mmol/L
4-AAP 0.9mmol/L
POD 2400 U/L
Ascorbate oxidase  2700 U/L
Antihuman ? lipoprotein antibody
Reagent 2 :
Goods buffer,   pH – 7.0 ; 30.0mmol/L
CHE 4000 U/L
CO  20000 U/L
F-DAOS 0.8 mmol/L
Calibrator : HDL-C  56.5 mg/dL
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Procedure  :  Reagent 1 & 2 were mixed in the ratio of 3:1 ( 1 bottle of reagent 1,
was mixed with 1 bottle of reagent 2 ) and placed in the auto analyser with the
following assay parameters:
Assay type : 2 point
Primary wavelength nm : 600, secondary wavelength nm : 700
R-1 volume : 270, R-2 volume : 90
Reaction direction : increasing, sample volume : 3 µL
Calibration : straight
Reference Values
Adult male : 35 – 80 mg /dL
Adult female : 40.0 – 90.0 mg / dL
VLDL and LDL Cholesterol :
These parameters were calculated using Friedwald’s formula given below (
not applicable if serum  Triglycerides exceeds 400 mg/dL )







1. Allele frequencies were calculated by allele counting.
2. Age, sex, smoking, alcoholism, BMI, plasma glucose, serum urea, serum
creatinine, serum lipid levels were compared between control subjects and
patients by students ‘ t’  test and chi-square test (?2 ).
3. Genotype frequency distribution between cases and controls were compared
with a ?2 test for 2*2 contingency table.
4. Serum NOx distribution between cases and controls were compared by
student independent t test. p < 0.05 was considered significant.
5. Serum NOx level was compared in different genotypes in the study group
using one way anova F test.
6. Logistic regression analysis was performed to evaluate the interaction
between human eNOS intron4 genotypes and other variables in relation to
the prevalence of essential hypertension. Independent variables included in
the analysis were age (quantitative ), sex (male/female), smoking(yes/no),
alcoholism (yes/no) , serum levels of glucose, urea, creatinine, cholesterol,
triglycerides  ,  HDL  (quantitative).  The  analysis  was  executed  by  SAS
Statistical program Version 6.10 for Macintos.
7. The influence of other biochemical parameters on serum NOx level was
analysed through Pearson correlation .
TABLE 3 :
CHARACTERISTICS OF PATIENTS WITH ESSENTIAL





Mean SD Mean SD
Age 50.59 10.52 51.83 11.60 t=0.94 P=0.36(NS)
Wt 66.23 9.78 64.42 10.39 t=1.51 P=0.13(NS)
Ht 163.78 6.88 162.15 7.75 t=1.86 P=0.06(NS)





N % n %
Sex Male 132 87.4% 118 90.1% ?2=0.49
P=0.48(NS)Female 19 12.6% 13 9.9%
Smoking No 116 76.8% 96 73.3% ?2=0.47
P=0.49(NS)Yes 35 23.2% 35 26.7%
Alcoholism No 122 81.5% 104 80.2% ?2=0.07
P=0.88(NS)Yes 28 18.5% 26 19.8%










BAR DIAGRAM 1  : COMPARISON OF GENOTYPE DISTRIBUTION



























* a+ represents aa & ab genotypes ;  a- represents bb genotype
TABLE 4 :
Genotype distribution and Allele frequencies of human










GENOTYPE DISTRIBUTION AND ALLELE FREQUENCIES OF HUMAN eNOS
INTRON 4 GENE
Genotype Hypertensives Control P value
a+* 45 (29.8%) 28 (21.4%) Chi sq = 0.45
p = 0.5a-* 105 (70.2%) 102 (78.6%)
SCATTER DIAGRAM : 1
PATTERN OF  DISTRIBUTION OF SERUM NOx LEVEL IN CASES AND
CONTROLS
Y axis – serum NOx concentration















Y axis – serum NOx concentration in µmol/L
TABLE 6 :





Mean SD Mean SD
SERUM NOx 14.69 4.45 18.16 7.23 t=4.91 P=0.001***









Serum NOx level 10.45 18.35 t = 11.42
p = 0.001














Study   a/a 7 7.457 1.6592
F=70.2
P=0.001
a/a Vs  b/b
a/b Vs  b/b
b/b Vs a/a, b/b
  a/b 38 10.513 3.3170
  b/b 105 16.671 3.2350
 Total 150 14.694        4.4478
Control   a/a 4 9.425 1.6761
F=22.6
P=0.001
a/a Vs  b/b
a/b Vs  b/b
b/b Vs a/a, b/b
  a/b 24 11.400 1.7245
  b/b 102 20.074 6.9632
 Total 130 18.160 7.2332
SCATTER DIAGRAM 2 :  PATTERN OF DISTRIBUTION OF SERUM NOx
LEVEL IN a+ GENOTYPIC INDIVIDUALS
Y axis – serum NOx concentration in µmol/L
SCATTER DIAGRAM 3 :  PATTERN OF DISTRIBUTION OF SERUM NOx
LEVEL IN a+ GENOTYPIC INDIVIDUALS
Y axis – serum NOx concentration in µmol/L
BAR DIAGRAM : 4
















Y axis – serum NOx concentration in µmol/L
























T.CHOL 162.88 31.13 164.12 42.73 t=0.28 P=0.77
TGL 163.99 48.37 165.09 58.33 t=0.17 P=0.86
HDL 38.04 7.70 44.42 12.00 t=5.38 P=0.001
LDL 96.62 37.44 88.44 37.25 t=1.83 P=0.07




AGE -.002 .928 .998 .952 1.046
SEX -.395 .657 .673 .117 3.865
SMOKING -1.394 .117 .248 .043 1.420
ALCOHOLIC 1.414 .155 4.114 .587 28.846
BMI .088 .116 1.092 .978 1.220
Bl.SUGAR .025 .448 1.025 .961 1.093
T.CHOL -.017 .446 .983 .941 1.027
TGL .002 .728 1.002 .990 1.015
HDL .025 .435 1.025 .963 1.090
LDL .022 .251 1.023 .984 1.062
NOx .765 .000 2.149 1.759 2.625
Constant -13.962 .001 .000
TABLE 11 :
CASE AND CONTROL GROUP CORRELATIONS OF SERUM NOx LEVEL
WITH OTHER BIOCHEMICAL PARAMETERS:
Type of statistical analysis
Plasma
glucose T.chol TGL HDL LDL SERUM NOx
Serum NOx level
Of controls
Pearson Correlation .070 .028 .157 -.015 -.038 1
Sig. (2-tailed) .429 .751 .073 .865 .669 .
N 130 130 130 130 130 130
Serum NOx
Of cases
Pearson Correlation -.026 .094 -.013 .055 .100 1
Sig. (2-tailed) .749 .251 .872 .503 .223 .
N 150 150 150 150 150 150
**  Correlation is significant at the 0.01 level (2-tailed).
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RESULTS
? Tables 1 & 2 are the master charts for various data in the study and control
groups respectively.
? Table  3  :  shows  age  ,  sex  ,   BMI   and  other  conventional  risk  factors
distribution in  patients and control subjects with  an insignificant p value.
? Pie  diagrams 1 & 2 show the pattern of distribution of various genotypes in
cases and controls respectively.
? Bar diagrams 1 & 2 compares the genotype distribution and allele
frequencies of human eNOS intron4 gene in patients with essential
hypertension and controls.  Homozygous ‘aa’ genotype was found to be
more prevalent in the hypertensives (4.6%), when compared to controls
(3.1%). In contrast, both homozygous ‘bb’ and heterozygous ‘ab’ were more
common in controls when compared with the hypertensives. But these
differences were not statistically significant, as represented in tables 4 & 5.
? Scatter diagrams 1  represents the distribution of serum NOx level in cases
and controls.
? Table  6  compares  serum  NOx  levels  of  cases  with  controls.  Statistically
significant low NOx levels, with p value of 0.001 was observed in cases
(14.69 + SD 4.45) when compared to controls (18.16 + SD  7.23),  as
represented  in bar diagram 3.
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? Scatter diagrams 2 & 3 represents the distribution of serum NOx level in a+
and a- genotypes.
?  Bar  diagram  4  compares  the  distribution  of  serum  NOx  level  in  various
genotypes.
? Table 7 & 8 shows the comparison of serum NOx between various genotypes
in both the groups. The activity was significantly lower among a+ genotype
individuals(10.45) when compared to a- genotype individuals (18.35) with a
significant p value.
? Table 9 shows the distribution of other biochemical parameters like plasma
glucose, serum urea, serum creatinine, lipid profile between hypertensives
and controls. HDL levels was found to be significantly lowered in cases.
? Table 10 shows the multiple logistic regression analysis, from which it was
found that  serum NOx level is an independent risk factor for hypertension.
? Table 11 shows pearson correlation analysis, from which it was found that
serum NOx level was not influenced by biochemical parameters like plasma




Genetic factors in combination with a number of environmental risk factors
are involved in essential hypertension. Endothelial dysfunction which is now
recognised to be the hallmark in the pathogenesis of essential hypertension, is
mainly caused by imbalance between vasoconstrictors and vasodilators . Nitric
oxide, the one considered to be the main factor involved in endothelial dysfunction,
is found to be  the main mediator involved in  shear stress. The effect of
physiological vasodilators like acetyl-choline, bradykinin and various therapeutic
vasodilators were found to exert their action mainly via NO pathway. The level of
NO was found to be altered in various hypertensive disorders . The lowered plasma
NO level may be attributed to various factors like reduced biosynthesis and
inactivation by free radicals. If it is due to reduced biosynthesis, it may be attributed
to polymorphisms at the gene level, reduced transcriptional activity of eNOS gene,
inactivation of eNOS and circulating eNOS inhibitors. Various studies are being
conducted to find the role of endothelial nitric oxide synthase gene in regulating
plasma NO level and in the pathogenesis of essential hypertension. The eNOS gene
is regulated by various factors from the level of transcription to mRNA decay as
shown in figure 16. Intron4 was found to affect the transcriptional efficiency of the
gene and its polymorphism is being studied in relation to essential hypertension.
This  study was performed   to seek for an apt report to  the following queries :
1. Is  serum nitric oxide level altered in case of essential hypertension?
Figure : 16
VARIOIUS LEVELS OF REGUALTION OF eNOS GENE.
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2. If so, whether the eNOS intron4 gene polymorphism is responsible for any
altered  effect?
3. Can eNOS intron4 polymorphism be considered as a risk factor for
developing essential hypertension ?
In this study, the hypertensives and controls were perfectly matched with
respect to  the confounding variables like age, sex, BMI, smoking and alcoholism.
Those with impaired glucose tolerance, renal failure, acute infections, chronic
inflammation and chronic smokers were excluded from the study as these states may
present with altered serum NOx level.
The main area of study was focused on serum NO level (  NOx index )  and
eNOS intron4 polymorphism screening ( genotypes aa , ab , bb ).
On comparing the serum NOx level of the hypertensives with the controls, it
was found to be significantly lowered in hypertensives ( 14.69 versus 18.16,
p=0.001 ). Previous studies (Afrasyap & Ozturk, 2004; Kumar & Das, 2000: Node,
K., Kitakaze, M., Yoshikawa, H., Kosaka, H., & Hori, M. (1997)) have shown
similar  supportive  results.Node  K  et  al  (1997),  in  fact  recorded  a  very  similar
decline in NO level in hypertensives when compared to controls. Different studies
showed a wide variation of the normal  range of NO (Ferlito, Gallina, Pitari, &
Bianchi, 1998; Klahr, 2001; Kumar & Das, 2000; Jeerooburkhan et al., 2001).  It is
quite obvious that the serum NO level is an independent risk indicator in essential
hypertension, based on this study.
71
In the present study the frequency of ‘a’ allele was found to be
approximately 0.26, which is little higher than that found in other populations viz.,
Iranian (0.1), Japanese (0.1 to 0.13) , Turkish (0.14), Australian (0.17) and little
lower than that of African Americans (0.28). The differences in the ethnic origin and
sample sizes  might have an influence in the results obtained regarding the
distribution of the eNOS intron4 polymorphism studied in these populations.
This  study  did  not  find  any  correlation  between the  presence  of  the  eNOS
4a/b variant and essential hypertension. This may be due to the small sample size.
According to the literature survey, only two studies, one on Caucasians in general
(Rodríguez-Esparragón, Rodríguez-Pérez, Macías-Reyes, & Alamo-Santana, 2003),
and another on the Ukrainian population (Dosenko, Zagoriy, Haytovich, Gordok, &
Moibenko, 2005), have shown a correlation between this polymorphism and
essential hypertension. No such correlation have been found in other studies
(Gouni-Berthold et al., 2005; Miyamoto et al., 1998; Zhao, Su, Chen, Li, & Gu,
2006 ).
Though intron 4a/b polymorphism of NOS3 had no association with
essential hypertension, a trend towards a higher frequency of the ‘a’ allele was
apparent in the hypertensives. In other studies conducted in India,  the same trend
was observed (T Padma et al., 2009 ; Kamna Srivastava et al., 2009 ). This study
needs to be expanded by conducting a large cohort study, to elucidate in depth, a
link of any association of essential hypertension with intron4 gene polymorphism.
On comparison of the serum NOx levels between the various genotypes (a+
genotype  and  a-  genotype),  there  was  a  significantly  lower  level  among a+ (aa  &
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ab) genotypic hypertensives and controls with a  p value was 0.001. This suggests
that a+ genotype is significantly associated with low serum NOx level. Based on the





? The low serum NOx level may be an independent risk factor for essential
hypertension.
? The eNOS intron4 polymorphism may exert an effect on serum NOx levels,
probably by altering the transcriptional efficiency.
? ‘a’ allelic persons were found to have lower level of serum NOx, when
compared to ‘b’ alleles.
? eNOS intron4 polymorphism was not found to be a risk factor for essential
hypertension in this study.
? The presence of ‘a’ allele makes a person more susceptible to essential
hypertension because of its nitric oxide lowering effect. ‘b’ allele was found
to be protective.
? As the study population was confined to the hypertensives attending a single
govt.general hospital, the expected role of eNOS intron4 polymorphism as a
risk factor could not be framed.
Scope for future study
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SCOPE FOR FURTHER STUDY
? This study needs to be expanded to cover a larger population, to define the
actual role of eNOS intron4 polymorphism in essential hypertension.
? A case-cohort study will probably unravel  the involvement of this gene
aberration in entire South Indian population, which was the aim before
commencing this study.
? Studies relating serum NOx level and antioxidant status have to be  explored.
? Studies may be further carried out to find the effect of rapid lifestyle
modification on serum NOx level and eNOS polymorphism.
? Various other eNOS genes have to be explored and their association with
eNOS activity and essential hypertension to be studied.
? Antihypertensive treatment regimens may be targetted to increase the serum
NO level by one of the following methods .
? to find newer NO donors.
? to inhibit eNOS inhibitors.
? to enhance the activity of sGC .
? to increase the transcriptional activity and to prolong mRNA half-life,
at the gene level.
? Studies relating to serum eNOS activity , nitro-tyrosine level and antioxidant
status in addition to NOx levels,  may be explored, to get a more precise NO
level.
? GENE THERAPY may be ventured if there is an association of the gene
polymorphism with essential hypertension.
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ABBREVIATIONS
ABBREVIATIONS
CHD - coronary heart disease
VLDL - very low density lipoprotein
LDL - low density lipoprotein
HDL - high density lipoprotein
EDRF - endothelium derived relaxing factor
MLCK - myosin light chain kinase
sGC - soluble guanylyl cyclase
PDE - phosphodiesterase
NO. -  nitric oxide
cGMP - cyclic guanosine mono-phosphate
GTP - guanosine tri-phosphate
cAMP - cyclic adenosine mono-phosphate
eNOS - endothelial nitric oxide synthase
iNOS -  inducible nitric oxide synthase
nNOS - neuronal nitric oxide synthase
RAAS - renin angiotensin aldesterone system
ACE - angiotensin converting enzyme
ENAC - epithelial sodium channels
OD - optical density
L-NAME - L-NG Nitroarginine methyl ester
RSNO - S-nitrosothiols
GSNOR - S-nitroso glutathione reductase
MPO - myeloperoxidase
ADMA - asymmetric dimethyl arginine
BH4 - tetra-hydro-biopterin
FAD - flavin adenine di-nucleotide
FMN - flavin mono-nucleotide
CaM - calmodulin
hsp - heat shock protein
IP3 - inositol 1,4,5 triphosphate
PRD - positive regulatory domain
TGF - transforming growth factor
BAEC - bovine aortic endothelial cells
HUVEC - human unbilical vein endothelial cells
TNF - tumor necrosing factor
Ox-LDL - oxidized - low density lipoprotein
VEGF - vascular endothelial growth factor
TSA - trichostatin A
EPR - electron paramagnetic resonance
GC-MS - gas chromatography- mass spectrometry
HPLC  - high performance liquid chromatography
NOx - nitrate+ nitrite
NR - nitrate reductase
G6PD - glucose-6-phosphate dehydrogenase
NED - N-naphthyl-ethylene diamine
Table 1
Master chart for cases
Blood
sugar serum serum eNOS intron4
fasting urea creatinine SERUM TOTAL genotype
Height (m) (mg/dl) (mg/dl) (mg/dl)  NITRITES(µmol/L)
1 75 M No No 60 1.6 160 23.44 94 40 0.68 143 173 30 78.4 17.2            b/b
2 54 M No No 80 1.56 156 32.87 102 26 0.78 218 355 33 114 12.8 b/b
3 60 M No No 65 1.6 160 25.39 97 36 0.59 212 285 31 124 13.1 b/b
4 60 M No No 65 1.53 153 27.77 106 38 0.68 104 98 29 55.4 9.8 b/b
5 75 M No No 72 1.61 161 27.78 102 25 0.87 164 266 35 75.8 21.1 b/b
6 54 M No No 56 1.66 166 20.32 84 29 0.96 159 110 52 85 22.1 b/b
7 61 M No No 60 1.66 166 21.77 96 36 1.1 207 155 27 149 8.9 a/b
8 44 M No No 74 1.59 159 29.27 92 38 1.06 221 154 36 154.2 14 b/b
9 53 M No No 68 1.64 164 25.28 102 37 0.76 145 130 34 85 6.7 a/a
10 34 M Yes Yes 65 1.55 155 27.06 101 36 0.59 208 260 54 102 9.8 a/b
11 60 M No No 75 1.65 165 27.55 104 26 0.76 136 189 37 61.2 11.8 b/b
12 38 M Yes Yes 59 1.6 160 23.05 100 29 0.89 238 147 57 151.6 23.7 a/b
13 57 M No No 87 1.7 170 30.10 98 34 0.96 212 188 32 142.4 10.2 b/b
14 45 F No No 86 1.57 157 34.89 93 32 0.95 153 108 29 102.4 13 b/b
15 52 F No No 74 1.48 148 33.78 86 31 0.86 188 183 30 121.4 6 a/b
16 60 M No No 69 1.68 168 24.45 103 25 0.79 195 250 25 120 17.8 b/b
17 55 M No No 61 1.63 163 22.96 104 36 0.69 193 275 28.6 109.4 15.4 b/b
18 61 M No No 63 1.54 154 26.56 95 37 0.87 185 132 32.6 126 9.8 a/b
19 40 M No No 66 1.67 167 23.67 84 24 1.04 149 183 23.8 88.6 9.7 a/a
20 48 M No No 59 1.68 168 20.90 89 25 0.9 198 98 31 147.4 21.3 b/b
21 54 M No No 77 1.7 170 26.64 103 37 0.86 134 130 53.4 54.6 10.9 a/b
22 50 M No No 65 1.65 165 23.88 95 25 0.76 130 109 52 56.2 17.9 b/b
23 67 M No No 57 1.6 160 22.27 108 31 0.59 116 85 43 56 16.9 b/b
24 48 M Yes No 55 1.65 165 20.20 88 26 0.96 194 137 39.6 127 19.5              b/b
25 43 M Yes Yes 60 1.65 165 22.04 97 29 0.58 127 176 36 55.8 21.6 b/b
26 60 M No No 96 1.6 160 37.50 89 34 0.96 143 138 33 82.4 10.3 a/b
27 35 F No No 64 1.55 155 26.64 105 31 0.95 173 102 42.2 110.4 16.9 b/b
28 55 M No No 54 1.53 153 23.07 93 25 0.87 146 271 34.3 57.5 13.8 b/b
29 40 M No No 67 1.71 171 22.91 98 37 1.03 212 194 38 135.2 16.4 b/b
30 47 M Yes No 73 1.63 163 27.48 105 40 1 206 153 41 134.4 11.1 a/b
31 56 M No No 75 1.61 161 28.93 95 32 0.97 147 113 33.5 90.9 15.7 b/b
32 63 M No No 67 1.72 172 22.65 101 31 0.9 114 201 45 28.8 18.9 b/b
33 52 M No No 75 1.71 171 25.65 86 35 0.8 123 197 52 31.6 11.7 a/b
34 59 M No No 62 1.68 168 21.97 94 37 0.84 149 187 28.1 83.5 21.9 b/b
35 52 M No No 64 1.65 165 23.51 102 26 0.71 120 134 34 59.2 10.8 a/b
36 55 M No No 60 1.63 163 22.58 84 27 0.73 149 123 36.4 88 9.8 a/b
37 70 M No No 53 1.52 152 22.94 96 36 0.69 156 130 38.2 91.8 5.8 a/a
38 53 M No No 56 1.63 163 21.08 92 27 0.93 138 156 26.4 80.4 11.3 a/b
39 53 M Yes Yes 55 1.62 162 20.96 102 28 0.82 143 151 33.6 79.2 17.5 b/b
40 28 M No No 52 1.56 156 21.37 98 37 0.74 138 162 45.1 60.5 11.4 a/b
41 63 M No No 54 1.66 166 19.60 92 25 0.69 162 92 38 105.6 17.9            b/b
BMI CHOL (mg/dl) TGL (mg/dl) HDL (mg/dl) LDL (mg/dl)7 Age Sex Smoking Alcoholism Wt. (Kg) Ht. (cm)
42 58 M No No 64 1.55 155 26.64 100 33 0.95 189 171 24 130.8 12.1 a/b
43 25 M Yes No 55 1.58 158 22.03 98 26 0.94 166 154 39 96.2 9.7 a/a
44 51 M No No 63 1.76 176 20.34 93 28 0.8 145 167 32 79.6 9.9 a/b
45 48 M Yes Yes 58 1.67 167 20.80 96 22 0.87 175 166 28 113.8 16.9 b/b
46 45 M Yes Yes 72 1.76 176 23.24 92 32 0.6 126 152 38.3 57.3 19.4 b/b
47 58 M No No 49 1.48 148 22.37 102 28 0.98 125 136 43 54.8 7.3 a/a
48 35 M No No 72 1.64 164 26.77 108 31 0.98 181 138 37.3 116.1 20.1 b/b
49 50 M No No 51 1.55 155 21.23 104 28 0.7 175 192 41 95.6 18.4 b/b
50 51 M No No 57 1.56 156 23.42 100 29 0.86 151 148 45 76.4 7.5 a/b
51 54 F No No 75 1.51 151 32.89 98 37 0.92 185 143 37 119.4 16.2 b/b
52 60 F No No 75 1.53 153 32.04 102 25 0.85 146 153 36 79.4 17.5 b/b
53 50 M Yes No 65 1.7 170 22.49 83 31 0.84 148 182 38 73.6 9.3 a/b
54 52 M Yes No 80 1.7 170 27.68 85 39 0.93 168 174 28 105.2 16.9 b/b
55 29 M Yes Yes 65 1.69 169 22.76 93 35 1.05 156 182 35 84.6 24.9 b/b
56 50 M No No 68 1.78 178 21.46 97 27 0.78 156 173 43 78.4 19.9 b/b
57 47 M No No 70 1.62 162 26.67 89 22 1.09 165 168 51 80.4 11.7 a/b
58 50 M No No 90 1.71 171 30.78 88 39 0.76 174 142 34 111.6 17.6 b/b
59 34 M Yes Yes 76 1.76 176 24.54 89 24 0.98 125 163 55 37.4 17.6 b/b
60 50 M No No 62 1.67 167 22.23 95 26 0.9 141 149 38 73.2 14.9 b/b
61 33 M Yes Yes 68 1.63 163 25.59 100 27 0.89 117 199 35.4 41.8 11.4 a/b
62 48 M Yes No 55 1.65 165 20.20 88 25 0.84 194 137 39.6 127 21.2  b/b
63 43 M Yes Yes 60 1.65 165 22.04 97 28 0.82 127 176 36 55.8 17.3 b/b
64 60 M No No 96 1.6 160 37.50 104 38 0.95 143 138 33 82.4 9.5 a/b
65 35 F No No 64 1.55 155 26.64 98 29 0.9 173 102 42.2 110.4 14.8 b/b
66 55 M No No 54 1.53 153 23.07 93 24 0.85 146 271 34.3 57.5 10.5 a/b
67 40 M No No 67 1.71 171 22.91 98 36 0.7 212 194 38 135.2 15.9 b/b
68 47 M Yes No 73 1.63 163 27.48 105 39 0.75 206 153 41 134.4 8.4 a/b
69 56 M No No 75 1.61 161 28.93 95 25 0.96 147 113 33.5 90.9 16.9 b/b
70 63 M No No 67 1.72 172 22.65 101 31 0.94 114 201 45 28.8 18.6 b/b
71 52 M No No 75 1.71 171 25.65 86 36 0.92 123 197 52 31.6 19.1 b/b
72 59 M No No 62 1.68 168 21.97 94 23 0.69 149 187 28.1 83.5 16.9 b/b
73 52 M No No 64 1.65 165 23.51 102 32 0.74 120 134 34 59.2 11.4 b/b
74 55 M No No 60 1.63 163 22.58 84 36 0.83 149 123 36.4 88 8.8 a/b
75 70 M No No 53 1.52 152 22.94 96 28 0.91 156 130 38.2 91.8 9.6 a/b
76 46 M No No 72 1.63 163 27.10 98 36 1.03 188 151 38 182 15.8 b/b
77 56 F No No 62 1.68 168 21.97 102 35 1.1 141 168 38 110 21.9 a/b
78 65 M Yes Yes 69 1.71 171 23.60 87 36 0.99 191 201 35 160 10.8 a/b
79 46 F No No 70 1.61 161 27.01 98 26 0.79 188 151 38 182 19.8 b/b
80 59 M No Yes 73 1.72 172 24.68 103 28 1.03 211 186 38 157 5.8 a/b
81 35 F No No 64 1.55 155 26.64 106 39 0.96 173 102 42.2 110.4 11.3 b/b
82 29 M Yes Yes 65 1.69 169 22.76 93 35 0.85 156 182 35 84.6 17.5 b/b
83 50 M No No 68 1.78 178 21.46 107 36 0.77 156 173 43 78.4 11.4 a/b
84 47 M No No 70 1.62 162 26.67 105 38 0.8 165 168 51 80.4 17.9 b/b
85 50 M No No 90 1.71 171 30.78 88 26 0.94 174 142 34 111.6 12.1 b/b
86 34 M Yes Yes 76 1.76 176 24.54 89 27 0.84 125 163 55 37.4 17.5 b/b
87 50 M No No 62 1.67 167 22.23 95 29 0.86 141 149 38 73.2 9.9 a/b
88 33 M Yes Yes 68 1.63 163 25.59 98 32 0.94 117 199 35.4 41.8 16.9 b/b
89 48 M Yes No 55 1.65 165 20.20 88 27 0.98 194 137 39.6 127 19.4 b/b
90 43 M Yes Yes 60 1.65 165 22.04 97 31 0.7 127 176 36 55.8 17.6 b/b
91 60 M No No 96 1.6 160 37.50 94 28 0.86 143 138 33 82.4 10.3 a/b
92 35 F No No 64 1.55 155 26.64 104 28 0.8 173 102 42.2 110.4 18.4 b/b
93 54 M No No 80 1.56 156 32.87 102 25 0.86 218 355 33 114 16.4 b/b
94 60 M No No 65 1.6 160 25.39 97 31 0.87 212 285 31 124 16.2 b/b
95 60 M No No 65 1.53 153 27.77 97 27 0.96 104 98 29 55.4 17.5 b/b
96 75 M No No 72 1.61 161 27.78 102 24 0.8 164 266 35 75.8 11.9 b/b
97 54 M No No 56 1.66 166 20.32 84 27 1.12 159 110 52 85 16.9 b/b
98 61 M No No 60 1.66 166 21.77 96 20 1.14 207 155 27 149 9.5 a/b
99 44 M No No 74 1.59 159 29.27 92 24 0.95 221 154 36 154.2 19.9 b/b
100 53 M No No 68 1.64 164 25.28 102 31 0.93 145 130 34 85 21.6 b/b
101 34 M Yes Yes 65 1.55 155 27.06 108 34 0.78 208 260 54 102 13.1 b/b
102 63 M No No 67 1.72 172 22.65 94 25 0.59 114 201 45 28.8 9.8 b/b
103 52 M No No 75 1.71 171 25.65 86 27 0.68 123 197 52 31.6 9.7 a/b
104 59 M No No 62 1.68 168 21.97 94 28 0.87 149 187 28.1 83.5 22.1 b/b
105 52 M No No 64 1.65 165 23.51 102 25 0.96 120 134 34 59.2 18.7 b/b
106 55 M No No 60 1.63 163 22.58 84 36 1.1 149 123 36.4 88 14 b/b
107 70 M No No 53 1.52 152 22.94 96 34 0.71 156 130 38.2 91.8 6.7 a/b
108 46 M No No 72 1.63 163 27.10 98 32 0.73 188 151 38 182 16.3 b/b
109 56 F No No 62 1.68 168 21.97 102 31 0.69 141 168 38 110 11.8 a/b
110 65 M Yes Yes 69 1.71 171 23.60 94 21 0.93 191 201 35 160 23.7 b/b
111 46 F No No 70 1.61 161 27.01 87 25 0.82 188 151 38 182 10.2 b/b
112 59 M No Yes 73 1.72 172 24.68 83 27 0.74 211 186 38 157 13 b/b
113 35 F No No 64 1.55 155 26.64 103 31 0.69 173 102 42.2 110.4 16.1 b/b
114 29 M Yes Yes 65 1.69 169 22.76 93 28 0.95 156 182 35 84.6 9.4 a/b
115 50 M No No 68 1.78 178 21.46 95 28 0.94 156 173 43 78.4 15.4 b/b
116 47 M No No 70 1.62 162 26.67 105 25 0.8 165 168 51 80.4 15.9 b/b
117 50 M No No 90 1.71 171 30.78 88 31 0.79 174 142 34 111.6 17.8 b/b
118 34 M Yes Yes 76 1.76 176 24.54 89 27 0.7 125 163 55 37.4 5.7 a/a
119 50 M No No 62 1.67 167 22.23 95 24 0.75 141 149 38 73.2 13.3 b/b
120 33 M Yes Yes 68 1.63 163 25.59 98 27 0.79 117 199 35.4 41.8 8.3 a/b
121 48 M Yes No 55 1.65 165 20.20 88 20 0.84 194 137 39.6 127 16.9 b/b
122 38 M Yes Yes 59 1.6 160 23.05 100 24 0.95 238 147 57 151.6 19.5 b/b
123 57 M No No 87 1.7 170 30.10 98 26 0.58 212 188 32 142.4 21.6 b/b
123 45 F No No 86 1.57 157 34.89 93 21 0.63 153 108 29 102.4 12.7 b/b
124 52 F No No 74 1.48 148 33.78 86 22 0.94 188 183 30 121.4 16.9 b/b
125 60 M No No 69 1.68 168 24.45 99 34 0.68 195 250 25 120 11 a/b
126 55 M No No 61 1.63 163 22.96 104 31 1.04 193 275 28.6 109.4 16.4 b/b
127 61 M No No 63 1.54 154 26.56 95 37 0.84 185 132 32.6 126 17.4 b/b
128 40 M No No 66 1.67 167 23.67 84 26 1.12 149 183 23.8 88.6 15.7 b/b
129 48 M No No 59 1.68 168 20.90 89 28 0.94 198 98 31 147.4 14.2 b/b
130 54 M No No 77 1.7 170 26.64 103 24 0.78 134 130 53.4 54.6 11.7 b/b
131 50 M No No 65 1.65 165 23.88 95 32 0.83 130 109 52 56.2 21.9 b/b
132 67 M No No 57 1.6 160 22.27 114 35 0.86 116 85 43 56 7.3 a/a
133 48 M Yes No 55 1.65 165 20.20 105 38 1.04 194 137 39.6 127 13.9 b/b
134 43 M Yes Yes 60 1.65 165 22.04 97 32 0.9 127 176 36 55.8 18.1 b/b
135 60 M No No 96 1.6 160 37.50 103 21 0.79 143 138 33 82.4 11.3 b/b
136 35 F No No 64 1.55 155 26.64 98 26 0.94 173 102 42.2 110.4 17.5 b/b
137 55 M No No 60 1.63 163 22.58 84 25 0.73 149 123 36.4 88 8.8 a/b
138 70 M No No 53 1.52 152 22.94 96 26 0.85 156 130 38.2 91.8 17.9 b/b
139 46 M No No 72 1.63 163 27.10 104 23 0.69 188 151 38 182 12.1 b/b
140 56 F No No 62 1.68 168 21.97 102 21 0.82 141 168 38 110 18.6 b/b
141 65 M Yes Yes 69 1.71 171 23.60 89 24 0.71 191 201 35 160 14.8 b/b
142 46 F No No 70 1.61 161 27.01 99 27 0.94 188 151 38 182 21.3 b/b
143 59 M No Yes 73 1.72 172 24.68 106 29 0.86 211 186 38 157 11.7 b/b
144 35 F No No 64 1.55 155 26.64 84 35 0.84 173 102 42.2 110.4 16.8 b/b
145 29 M Yes Yes 65 1.69 169 22.76 93 34 0.82 156 182 35 84.6 14.9 b/b
146 50 M No No 68 1.78 178 21.46 107 37 0.79 156 173 43 78.4 16.2 b/b
147 47 M No No 70 1.62 162 26.67 105 25 0.65 165 168 51 80.4 13.8 b/b
148 50 M No No 90 1.71 171 30.78 88 23 0.73 174 142 34 111.6 17.4 b/b
149 34 M Yes Yes 76 1.76 176 24.54 89 32 0.76 125 163 55 37.4 13.8 b/b




plasma serum serum eNOS
glucose urea creatinine SERUM TOTAL Intron4 genotype
fasting (mg/dl) (mg/dl)  NITRITES(µmol/L)
(mg/dl)
1 45 M No No 70 1.6 27.04 98 24 1.1 110 136 51.4 31.4 17.2 b/b
2 74 F No No 50 1.5 22.22 89 27 1.06 149 189 33.5 77.7 18.5 b/b
3 50 M No No 60 1.55 25 101 37 0.96 134 151 34.6 69.2 17 b/b
4 55 M No No 70 1.64 26.92 87 26 0.95 150 278 31.9 62.5 73 b/b
5 88 M No No 65 1.59 25.79 98 28 0.86 149 278 31.9 61.5 15.5 a/b
6 50 M No No 68 1.58 27.24 94 24 0.79 145 120 57.5 63.5 34.8 b/b
7 74 M No No 60 1.6 23.44 100 32 0.69 121 125 42.8 53.2 14.6 a/b
8 60 F No No 70 1.55 29.14 104 35 0.87 129 109 55 52.2 38.1 b/b
9 80 M No No 50 1.5 22.22 87 27 0.86 180 243 38 93.4 23.3 b/b
10 52 M yes yes 70 1.6 27.34 82 24 0.76 149 96 47.6 82.2 12.2 b/b
11 65 M No No 80 1.7 27.68 95 27 0.59 136 230 45 45 14.2 b/b
12 61 M No No 60 1.58 24.03 94 20 0.96 149 248 48 51.4 21.1 b/b
13 65 M No No 55 1.54 23.19 85 24 0.58 152 52 75 66.6 13.5 b/b
14 60 M No No 85 1.75 27.76 82 26 0.96 110 142 38.6 43 8 a/b
15 72 M No No 75 1.7 25.95 94 32 1 164 107 55.3 87.3 17.3 b/b
16 70 M No No 85 1.78 26.83 102 31 0.97 140 203 38.1 61.3 14.5 b/b
17 69 M No No 60 1.7 20.76 95 21 0.9 161 200 41.2 79.8 14.6 b/b
18 50 F No No 75 1.55 31.22 81 25 0.8 192 121 51 116.8 23.5 b/b
19 50 M No No 80 1.5 35.56 104 27 0.84 156 72 58 83.6 11.5 a/b
20 60 M No No 65 1.65 23.88 92 31 0.71 148 75 39 94 23.6 b/b
21 86 M No No 60 1.7 20.76 96 20 0.87 138 81 42 79.8 15.1 b/b
22 48 M yes yes 70 1.6 27.34 93 24 0.6 230 281 82 91.8 28.5 b/b
23 50 M No No 55 1.5 24.44 84 31 0.98 201 244 62.4 89.8 21.1 b/b
24 40 M No No 72 1.6 28.13 89 34 0.98 157 303 43 53.4 21.8 b/b
25 60 M No No 61 1.63 22.96 95 25 0.7 147 131 72 48.8 31.6 b/b
26 70 F No No 65 1.58 26.04 91 27 0.86 132 145 53 50 9.6 a/b
27 50 M No No 80 1.65 29.38 92 32 0.9 159 148 45 84.4 24.9 b/b
28 50 F No No 68 1.58 27.24 85 27 0.89 144 128 53 65.4 17.5 b/b
29 60 M yes yes 65 1.53 27.77 88 31 0.84 224 336 48.2 108.6 21.4 b/b
30 67 M No No 90 1.8 27.78 84 28 0.82 132 128 54 52.4 19.8 b/b
31 48 M No No 72 1.71 24.62 97 28 0.95 152 52 75 66.6 14.1 b/b
32 40 M No No 50 1.65 18.37 84 25 0.9 160 173 42.3 83.1 11.1 a/b
33 45 M yes yes 45 1.5 20 103 36 0.85 149 189 53.5 57.7 14.7 b/b
34 60 M yes yes 65 1.61 25.08 92 26 0.91 322 300 74.7 187.3 18.4 b/b
35 75 M No No 50 1.5 22.22 87 28 1.03 208 295 41.5 107.5 21.7 b/b
36 41 M No No 65 1.5 28.89 81 39 1.1 174 116 51 99.8 18 b/b
37 52 M yes yes 55 1.62 20.96 95 35 0.99 221 293 45.8 116.6 17.4 b/b
38 59 M No No 55 1.7 19.03 82 36 0.79 310 370 60 176 10.5 a/b
39 54 M No No 55 1.55 22.89 96 39 1.03 215 294 50.2 106 23.2 b/b
40 60 M yes No 50 1.5 22.22 91 25 0.98 219 152 73.9 114.7 8.2 a/a
41 50 M yes yes 60 1.57 24.34 104 31 0.7 194 155 47 116 21.5 b/b
42 60 M yes yes 42 1.5 18.67 84 36 0.86 170 101 45.8 104 19.6 b/b
43 55 M No No 55 1.55 22.89 96 23 0.8 149 83 42.6 89.8 10.1 a/b
44 65 M No No 55 1.54 23.19 101 32 0.86 193 128 54 113.4 18.2 b/b
45 60 F No No 50 1.55 20.81 104 39 0.87 368 244 75.7 243.5 16.4 b/b
46 60 M No No 74 1.6 28.91 85 24 0.78 356 273 76.6 224.8 17.2 b/b
47 40 M No No 70 1.6 27.34 82 26 0.59 154 119 61 69.2 14.3 b/b
48 44 M No No 75 1.7 25.95 95 27 0.68 210 271 47.5 108.3 18.7 b/b
49 55 F No No 68 1.65 24.98 89 25 0.87 210 151 55.1 124.7 16 b/b
50 60 M yes No 65 1.6 25.39 104 28 0.96 105 95 48 38 9.2 a/b
BMI CHOL (mg/dl) TGL (mg/dl) HDL (mg/dl) LDL (mg/dl)Sl. No Age Sex smoking Alcoholism Wt. (Kg) Height(m)
51 55 M yes yes 50 1.6 19.53 83 31 1.1 147 132 51 69.6 21 b/b
52 45 M yes yes 65 1.58 26.04 102 28 0.71 143 138 41 74.4 17.2 b/b
53 40 M yes No 68 1.6 26.56 88 29 0.7 151 132 45.2 79.4 10.9 a/b
54 48 M No No 53 1.58 21.23 94 37 0.75 153 130 46.7 80.3 18.1 b/b
55 36 M No No 65 1.65 23.88 99 25 0.79 136 125 38.5 72.5 15.7 b/b
56 40 M No No 59 1.64 21.94 92 31 0.84 153 80 53 84 17.5 b/b
57 42 M No No 58 1.58 23.23 89 27 0.95 161 137 56 77.6 13.1 a/b
58 49 M No No 53 1.58 21.23 86 28 0.58 281 217 81.5 156.1 17.2 b/b
59 32 M No No 55 1.54 23.19 83 37 0.63 210 280 45.1 108.9 8.9 a/a
60 48 M yes No 75 1.6 29.3 89 27 0.94 162 159 56 74.2 24.7 b/b
61 49 M No No 70 1.65 25.71 105 32 0.94 188 112 50.4 115.2 21.5 b/b
62 52 M No No 64 1.65 23.51 102 26 0.78 120 134 34 59.2 16.8 b/b
63 55 M No No 60 1.63 22.58 84 25 0.83 149 123 36.4 88 18.6 b/b
64 70 M No No 53 1.52 22.94 96 37 0.86 156 130 38.2 91.8 17.6 b/b
65 53 M No No 56 1.63 21.08 92 40 1.04 138 156 26.4 80.4 12.1 a/b
66 53 M Yes Yes 55 1.62 20.96 102 32 0.9 143 151 33.6 79.2 18.6 b/b
67 28 M No No 52 1.56 21.37 108 31 0.79 138 162 45.1 60.5 19.3 b/b
68 63 M No No 54 1.66 19.60 105 35 0.94 162 92 38 105.6 13.2 b/b
69 58 M No No 64 1.55 26.64 100 37 0.79 189 171 24 130.8 10.8 a/b
70 25 M Yes No 55 1.58 22.03 98 24 0.94 166 154 39 96.2 17.8 b/b
71 51 M No No 63 1.76 20.34 93 25 0.73 145 167 32 79.6 19.7 b/b
72 48 M Yes Yes 58 1.67 20.80 96 37 0.85 175 166 28 113.8 23.8 b/b
73 45 M Yes Yes 72 1.76 23.24 92 25 0.69 126 152 38.3 57.3 9.8 a/b
74 58 M No No 49 1.48 22.37 102 31 0.82 125 136 43 54.8 29.7 b/b
75 35 M No No 72 1.64 26.77 108 38 0.71 181 138 37.3 116.1 18.6 b/b
76 50 M No No 51 1.55 21.23 103 37 0.65 175 192 41 95.6 19.5 b/b
77 51 M No No 57 1.56 23.42 100 36 0.87 151 148 45 76.4 21.1 b/b
78 54 F No No 75 1.51 32.89 98 26 1.09 185 143 37 119.4 21.4 b/b
79 60 F No No 75 1.53 32.04 102 29 0.67 146 153 36 79.4 23.6 b/b
80 50 M Yes No 65 1.7 22.49 97 34 0.87 148 182 38 73.6 12.1 a/b
81 52 M Yes No 80 1.7 27.68 85 26 0.95 168 174 28 105.2 24.5 b/b
82 29 M Yes Yes 65 1.69 22.76 93 36 0.86 156 182 35 84.6 19.6 b/b
83 50 M No No 68 1.78 21.46 100 38 1.04 156 173 43 78.4 16.8 b/b
84 47 M No No 70 1.62 26.67 102 25 0.95 165 168 51 80.4 17.8 b/b
85 50 M No No 90 1.71 30.78 88 29 0.84 174 142 34 111.6 17.5 b/b
86 34 M Yes Yes 76 1.76 24.54 89 29 0.96 125 163 55 37.4 10.8 a/b
87 50 M No No 62 1.67 22.23 92 34 0.9 141 149 38 73.2 18.7 b/b
88 33 M Yes Yes 68 1.63 25.59 95 32 0.79 117 199 35.4 41.8 11.9 a/a
89 48 M Yes No 55 1.65 20.20 88 31 0.75 194 137 39.6 127 18.9 b/b
89 43 M Yes Yes 60 1.65 22.04 97 25 0.73 127 176 36 55.8 18.8 b/b
90 60 M No No 96 1.6 37.50 102 25 0.94 143 138 33 82.4 22.9 b/b
91 35 F No No 64 1.55 26.64 103 31 0.9 173 102 42.2 110.4 21.9 b/b
92 55 M No No 54 1.53 23.07 93 26 0.7 146 271 34.3 57.5 19.7 b/b
93 40 M No No 67 1.71 22.91 98 29 1.05 212 194 38 135.2 22.6 b/b
94 47 M Yes No 73 1.63 27.48 95 34 0.69 206 153 41 134.4 12.1 a/b
95 56 M No No 75 1.61 28.93 95 31 1.1 147 113 33.5 90.9 11.9 a/b
96 63 M No No 67 1.72 22.65 103 25 0.8 114 201 45 28.8 16.8 b/b
97 52 M No No 75 1.71 25.65 86 35 0.76 123 197 52 31.6 18.7 b/b
98 59 M No No 62 1.68 21.97 94 37 0.74 149 187 28.1 83.5 17.9 b/b
99 52 M No No 64 1.65 23.51 102 26 0.93 120 134 34 59.2 19.7 b/b
100 55 M No No 60 1.63 22.58 84 27 0.8 149 123 36.4 88 12.6 a/b
101 70 M No No 53 1.52 22.94 96 36 0.96 156 130 38.2 91.8 23.6 b/b
102 46 M No No 72 1.63 27.10 89 33 0.84 188 151 38 182 8.7 a/a
103 56 F No No 62 1.68 21.97 102 26 0.63 141 168 38 110 13.8 b/b
104 65 M Yes Yes 69 1.71 23.60 83 28 0.82 191 201 35 160 9.7 b/b
105 46 F No No 70 1.61 27.01 102 22 0.91 188 151 38 182 17.9 b/b
106 59 M No Yes 73 1.72 24.68 103 32 0.97 211 186 38 157 30.6 b/b
107 35 F No No 64 1.55 26.64 99 28 0.95 173 102 42.2 110.4 13.8 a/b
108 29 M Yes Yes 65 1.69 22.76 93 31 0.86 156 182 35 84.6 17.8 b/b
109 50 M No No 68 1.78 21.46 105 24 1.04 156 173 43 78.4 15.8 b/b
110 47 M No No 70 1.62 26.67 97 35 0.89 165 168 51 80.4 17.7 b/b
111 50 M No No 90 1.71 30.78 88 37 0.86 174 142 34 111.6 18.9 b/b
112 34 M Yes Yes 76 1.76 24.54 89 41 0.7 125 163 55 37.4 12.9 b/b
113 50 M No No 62 1.67 22.23 95 25 0.71 141 149 38 73.2 23.6 b/b
114 33 M Yes Yes 68 1.63 25.59 104 36 0.84 117 199 35.4 41.8 19.7 b/b
115 45 M No No 53 1.52 22.94 96 34 1.1 156 130 38.2 91.8 17.6 b/b
116 64 M No No 56 1.63 21.08 92 37 1 138 156 26.4 80.4 12.1 a/b
117 54 M Yes Yes 55 1.62 20.96 102 25 0.98 143 151 33.6 79.2 18.6 b/b
118 38 M No No 52 1.56 21.37 108 37 0.9 138 162 45.1 60.5 19.3 b/b
119 42 M No No 54 1.66 19.60 105 34 0.87 162 92 38 105.6 13.2 b/b
120 59 M No No 64 1.55 26.64 100 26 0.85 189 171 24 130.8 10.8 a/b
121 37 M Yes No 55 1.58 22.03 98 28 0.84 166 154 39 96.2 17.8 b/b
122 47 M No No 63 1.76 20.34 93 34 0.86 145 167 32 79.6 19.7 b/b
123 52 M Yes Yes 58 1.67 20.80 96 39 0.75 175 166 28 113.8 23.8 b/b
124 48 M Yes Yes 72 1.76 23.24 92 34 0.69 126 152 38.3 57.3 9.8 a/b
125 39 M No No 49 1.48 22.37 102 25 1.07 125 136 43 54.8 29.7 b/b
126 44 M No No 72 1.64 26.77 108 25 0.59 181 138 37.3 116.1 18.6 b/b
127 53 M No No 51 1.55 21.23 103 26 0.68 175 192 41 95.6 19.5 b/b
128 47 M No No 70 1.62 26.67 102 23 0.87 165 168 51 80.4 17.8 b/b
129 50 M No No 90 1.71 30.78 88 21 0.96 174 142 34 111.6 17.5 b/b
130 34 M Yes Yes 76 1.76 24.54 89 22 0.93 125 163 55 37.4 10.8 a/b

